Dr Andrew Somogyi
Professor
School of Biomedicine
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Professor Andrew Somogyi is a practicing pharmacist, having graduated from the Tasmanian College of Advanced Education in 1972. He undertook a higher degree (Master of Science-1978) and then PhD (1982) at Sydney University, School of Pharmacy. Andrew then undertook postdoctoral research at the Medical Hospital of the University of Bonn in Germany for 2.5 years under the mentorship of Prof Roland Gugler and Prof Michel Eichelbaum. Following a short period in Melbourne at the then Baker Medical Research Institute in Melbourne, he was recruited as a Research Fellow to the Department of Clinical & Experimental Pharmacology at the University of Adelaide in late 1982. In 1992 he was appointed as Senior Lecturer, then promoted to Associate Professor (1994) and Professor in 2002. He was Deputy Head of the Department between 1992 and 2010. Between May 2005 and December 2010, he was Associate Dean (Research) of the Faculty of Health Sciences. In 2010 he was made an Honorary Fellow of the Faculty of Pain Medicine the Australian and New Zealand College of Anaesthetists.
Andrew teaches pharmacology in undergraduate medicine, dentistry, nursing and health science programs. He has an active research program centred on elucidating the dispositional mechanisms for altered human drug response in pain therapeutics, cancer and transplantation through pharmacokinetic, metabolism, pharmacodynamic and pharmacogenomic studies. He has translated his research into clinical practice by establishing a Pharmacogenetics Service at the Royal Adelaide Hospital. Pharmacogenomics and personalised healthcare is a theme of his overarching research and public health focus.
He provides regular consultancy on the role of pharmacogenomics in adverse drug reactions to clinicians, patients and the legal profession Australia-wide.
- My Research
- Career
- Publications
- Grants and Funding
- Teaching
- Supervision
- Professional Activities
- Contact
RESEARCH PROJECTS AVAILABLE: Clinical Pharmacogenomics Research Group
Research Project 1
Title: Why do Aboriginal Australians respond differently to European when given medicines
Project description: Aboriginal Australians are vulnerable to not responding as well or better to medicines than Europeans because of their genetic make-up or can have life threatening adverse reactions. By knowing more about the genes that are involved we will be in a better position to personalise medicines for Aboriginal Australians. Our current research has identified that we can do a much better job of identifying why some medicines work better, some worse and why some can cause serious toxicity. We are currently working on statin medicines for reducing cholesterol and in chemotherapy for childhood leukaemia. This project would be ideally suited for a person interested in research into disadvantages peoples in Australia.
Research Project 2
Title:The genetics of acute, chronic and postoperative pain therapy with opioids
Project description: More and more people have chronic pain and more undergo surgery which causes acute pain than candevelop into chronic pain. When we give opioids for such pain relief, the doses can vary 10-fold and some get severe side effects. The reasons are mainly due to the patients genetic make-up and we have studied this overt the past decade. New findings show that it is not just their genetic make-up but their epigenetic make up. We have cohorts of patients that we are studying that include those of European ancestry but also Han Chinese, Malay and Indian. We have shown that ethnicity plays a very important role and we want to study this further. We have acute pain patients, cancer patients and patients who having had surgery go on to develop chronic persistent pain. The latter includes a trial of ketamine to attenuate this postsurgical pain. We look at the genetics of the drugs such as morphine and ketamine in terms of their receptors and pharmacokinetics. There are 3 projects, 1 each in : acute pain, chronic cancer pain, chronic post surgical pain.
Research Project 3
Title: Biomarker determinants of ketamine for treatment -resistant depression
Project description: We are the trial site for biomarker analysis of a large NHMRC funded clinical trial for investigating the efficacy and side effects to ketamine for treatment-resistant depression. Upto now the antidepressants that are prescribed work in less than 1 of 4 patients and takes upto 8 weeks to work, which is a poor outcome. Ketamine is a potential new therapy which is very rapid acting within 4 hours. We need to have a beter understanding of the dose, why some don’t respond and why some get unacceptable side effects. Our site will investigate this by measuring blood concentrations and the genetics of the target sites. Over 300 patients are being recruited so you will be part of a large national group of investigators, the outcome of which may mean a new approved therapy for depression.
Projects available for:list as appropriate
Honours / HDR / Masters
Location:
Helen Mayo Building;
Research project start:
Semester 1 and 2
Special requirements:
vaccination required
-
Appointments
Date Position Institution name 2005 - 2009 Associate Dean (Research) University of Adelaide 2002 - ongoing Professor in Clinical and Experimental Pharmacology University of Adelaide 1998 - 1998 Acting Head of Department University of Adelaide 1994 - ongoing Associate Professor University of Adelaide 1992 - 1993 Acting Head of Department University of Adelaide 1992 - 2010 Deputy Head of Department University of Adelaide 1991 - 1993 Senior Lecturer University of Adelaide 1989 - 1991 Senior Research Officer University of Adelaide 1987 - 1988 Visiting Lecturer University of Adelaide 1986 - 1988 Florey Research Fellow Royal Adelaide Hospital 1983 - 1985 Senior Research Officer (NH&MRC) University of Adelaide 1983 - ongoing Honorary Pharmacologist Royal Adelaide Hospital 1982 - 1982 Research Associate University of Adelaide 1981 - 1982 Senior Research Officer (NH&MRC) Baker Medical Research Institute and Alfred Hospital 1980 - 1980 Scientific Officer University of Bonn 1974 - 1977 Tutor Sydney University -
Education
Date Institution name Country Title 1975 - 1978 University of Sydney Australia Doctor of Philosophy (Ph.D) 1974 - 1975 University of Sydney Australia Master of Science (M.Sc) 1973 - 1973 University of Sydney Australia Diploma of Hospital Pharmacy 1969 - 1972 Tasmanian College of Advanced Education/ University of Tasmania Australia Certificate of Pharmacy (Ph. C) -
Postgraduate Training
Date Title Institution Country 2010 Fellow Faculty of Pain Medicine Australian and New Zealand College of Anaesthetists Australia -
Research Interests
-
Journals
Year Citation 2024 Martin, D. M., Harvey, A. J., Baune, B., Berk, M., Carter, G. L., Dong, V., . . . Loo, C. K. (2024). Cognitive outcomes from the randomised, active-controlled Ketamine for Adult Depression Study (KADS). Journal of affective disorders, 352, 163-170.
Scopus12024 Barratt, D. T., Klepstad, P., Dale, O., Kaasa, S., & Somogyi, A. A. (2024). Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects.. The Pharmacogenomics Journal, 24(3), 18-1-18-8.
2024 Robinson, K. M., Eum, S., Desta, Z., Tyndale, R. F., Gaedigk, A., Crist, R. C., . . . Kharasch, E. D. (2024). Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy. Clinical Pharmacology and Therapeutics, 116(4), 932-938.
Scopus2 Europe PMC12024 Somogyi, A., & Chesnot, V. (2024). Glass packaging and its contribution to the UN Sustainable Development Goals. INTERNATIONAL JOURNAL OF APPLIED GLASS SCIENCE, 15(4), 342-349.
2024 Wong, A. K., Klepstad, P., Somogyi, A. A., Vogrin, S., Rubio, J., Le, B., & Philip, J. (2024). Influence of COMT (rs4680) and OPRM1 (rs1799971) on Cancer Pain, Opioid Dose, and Adverse Effects. Journal of Palliative Medicine, 10 pages.
2024 Loo, C., Glozier, N., Barton, D., Baune, B. T., Mills, N. T., Fitzgerald, P., . . . Rodgers, A. (2024). Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial - CORRIGENDUM. The British journal of psychiatry : the journal of mental science, 225(2), 349.
2024 Wong, A. K., Klepstad, P., Rubio, J. P., Somogyi, A. A., Vogrin, S., Le, B., & Philip, J. (2024). Opioid Switch Dosing in Chronic Cancer Pain: A Prospective Longitudinal Study. Journal of Palliative Medicine, 27(3), 388-393.
2024 Wong, A. K., Vogrin, S., Le, B., Klepstad, P., Rubio, J. P., Somogyi, A. A., & Philip, J. (2024). Background and Breakthrough Opioid Choice May Determine Different Pain Outcomes. Journal of Pain and Symptom Management, 67(3), e259-e261.
2023 Toner, A. J., Bailey, M. A., Schug, S. A., Phillips, M., Ungerer, J. P. J., Somogyi, A. A., & Corcoran, T. B. (2023). Serum lidocaine (lignocaine) concentrations during prolonged perioperative infusion in patients undergoing breast cancer surgery: A secondary analysis of a randomised controlled trial. Anaesthesia and Intensive Care, 51(6), 422-431.
2023 Schwartz, O. S., Amminger, P., Baune, B. T., Bedi, G., Berk, M., Cotton, S. M., . . . Davey, C. G. (2023). The Study of Ketamine for Youth Depression (SKY-D): study protocol for a randomised controlled trial of low-dose ketamine for young people with major depressive disorder. Trials, 24(1), 686.
Scopus12023 Gammal, R. S., Pirmohamed, M., Somogyi, A. A., Morris, S. A., Formea, C. M., Elchynski, A. L., . . . Relling, M. V. (2023). Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.. Clinical pharmacology and therapeutics, 113(5), 973-985.
Scopus19 WoS5 Europe PMC132023 Philip, J., Wong, A., Pasanen, L., Somogyi, A. A., Rubio, J., Klepstad, P., . . . Le, B. (2023). Establishing a Longitudinal Opioid Pharmacogenomic Registry for Cancer Patients: Feasibility and Acceptability. Journal of Palliative Medicine, 26(3), 411-417.
Scopus42023 Lewis, G. N., Rice, D. A., Rashid, U., McNair, P. J., Kluger, M. T., & Somogyi, A. A. (2023). Trajectories of Pain and Function Outcomes up to 5 to 8 Years Following Total Knee Arthroplasty. Journal of Arthroplasty, 38(8), 1516-1521.
Scopus3 Europe PMC22023 Chiang, D. L. C., Rice, D. A., Helsby, N. A., Somogyi, A. A., & Kluger, M. T. (2023). The incidence, impact, and risk factors for moderate to severe persistent pain after breast cancer surgery: a prospective cohort study. Pain Medicine (United States), 24(9), 1023-1034.
Scopus6 Europe PMC22023 Ferlini Agne, G., May, B. E., Lovett, A., Simon, O., Steel, C., Santos, L., . . . Franklin, S. (2023). Horse Grimace Scale Does Not Detect Pain in Horses with Equine Gastric Ulcer Syndrome. Animals, 13(10), 12 pages.
Scopus4 Europe PMC12023 Ferlini Agne, G., Somogyi, A. A., Sykes, B., Knych, H., & Franklin, S. (2023). Identification and kinetics of microsomal and recombinant equine liver cytochrome P450 enzymes responsible for in vitro metabolism of omeprazole.. Biochem Pharmacol, 214, 1-7.
2023 Wong, A. K., Somogyi, A. A., Rubio, J., Pham, T. D., Le, B., Klepstad, P., & Philip, J. (2023). Effectiveness of Opioid Switching in Advanced Cancer Pain: A Prospective Observational Cohort Study. Cancers, 15(14), 1-11.
Scopus3 Europe PMC12023 Loo, C., Glozier, N., Barton, D., Baune, B., Mills, N., Fitzgerald, P. B., . . . Rodgers, A. (2023). Efficacy and Safety of Repeated Subcutaneous Ketamine Injections for Treatment Resistant Depression - The KADS Study: A Randomised, Double-Blind, Comparator-Controlled Trial. British Journal of Psychiatry, 223(6), 533-541.
Scopus21 WoS6 Europe PMC72023 Wong, A. K., Klepstad, P., Somogyi, A. A., Vogrin, S., Le, B., Philip, J., & Rubio, J. P. (2023). Effect of gene variants on opioid dose, pain and adverse effect outcomes in advanced cancer: an explorative study. Pharmacogenomics, 24(18), 901-913.
2022 Wong, A. K., Somogyi, A. A., Rubio, J., & Philip, J. (2022). The Role of Pharmacogenomics in Opioid Prescribing.. Curr Treat Options Oncol, 23(10), 1353-1369.
Scopus13 WoS1 Europe PMC52022 Somogyi, A. A., Musolino, S. T., & Barratt, D. T. (2022). New pharmacological perspectives and therapeutic options for opioids: Differences matter. Anaesthesia and Intensive Care, 50(1-2), 127-140.
Scopus5 WoS3 Europe PMC32022 Thomas, J. H. L., Lui, L., Abell, A., Tieu, W., Somogyi, A. A., Bajic, J. E., & Hutchinson, M. R. (2022). Toll-Like Receptors change morphine-induced antinociception, tolerance and dependence: studies using male and female TLR and Signalling gene KO mice. Brain, Behavior, and Immunity, 102, 71-85.
Scopus10 WoS7 Europe PMC52022 Kisely, S., Connor, M., Somogyi, A. A., & Siskind, D. (2022). A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders.. Aust N Z J Psychiatry, 57(3), 17 pages.
Scopus15 WoS8 Europe PMC62022 Abuhelwa, A. Y., Somogyi, A. A., Loo, C. K., Glue, P., Barratt, D. T., & Foster, D. J. R. (2022). Population pharmacokinetics and pharmacodynamics of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression.. Clin Pharmacol Ther, 112(3), 720-729.
Scopus6 WoS3 Europe PMC52022 Kluger, M. T., Rice, D. A., Borotkanics, R., Lewis, G. N., Somogyi, A. A., Barratt, D. T., . . . McNair, P. J. (2022). Factors associated with persistent opioid use 6-12 months after primary total knee arthroplasty.. Anaesthesia, 77(8), 882-891.
Scopus8 WoS2 Europe PMC32021 Rowsell, L., Wu, J. G. -A., Yee, B. J., Wong, K. K. H., Sivam, S., Somogyi, A. A., . . . Wang, D. (2021). The effect of acute morphine on sleep in male patients suffering from sleep apnea: Is there a genetic effect? An RCT study. Journal of Sleep Research, 30(4), 1-8.
Scopus4 WoS22021 Crews, K. R., Monte, A. A., Huddart, R., Caudle, K. E., Kharasch, E. D., Gaedigk, A., . . . Skaar, T. C. (2021). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy. Clinical pharmacology and therapeutics, 110(4), 888-896.
Scopus230 WoS151 Europe PMC1402021 Desta, Z., El-Boraie, A., Gong, L., Somogyi, A. A., Lauschke, V. M., Dandara, C., . . . Gaedigk, A. (2021). PharmVar GeneFocus: CYP2B6.. Clin Pharmacol Ther, 110(1), 82-97.
Scopus41 WoS25 Europe PMC232021 Sallustio, B. C., Noll, B. D., Hu, R., Barratt, D. T., Tuke, S. J., Coller, J. K., . . . Somogyi, A. A. (2021). Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. British Journal of Clinical Pharmacology, 87(10), 3901-3909.
Scopus17 WoS12 Europe PMC102021 Barratt, D. T., Sia, A. T., Tan, E. -C., & Somogyi, A. A. (2021). Innate immune and neuronal genetic markers are highly predictive of postoperative pain and morphine patient-controlled analgesia requirements in Indian but not Chinese or Malay hysterectomy patients. Pain Medicine, 22(11), 2648-2660.
Scopus5 WoS2 Europe PMC32021 Bordin Andriguetti, N., Barratt, D. T., Tucci, J., Pumuye, P., & Somogyi, A. A. (2021). Instability of Efavirenz Metabolites Identified During Method Development and Validation. J Pharm Sci, 110(10), 3362-3366.
Scopus4 Europe PMC12021 Bordin Andriguetti, N., Van Schalkwyk, H. K., Barratt, D. T., Tucci, J., Pumuye, P., & Somogyi, A. A. (2021). Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele. Clinical and Translational Science, 14(6), 2521-2531.
Scopus7 WoS4 Europe PMC32021 Karnes, J. H., Rettie, A. E., Somogyi, A. A., Huddart, R., Fohner, A. E., Formea, C. M., . . . Callaghan, J. T. (2021). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes and phenytoin dosing: 2020 update. Clinical Pharmacology and Therapeutics, 109(2), 302-309.
Scopus101 WoS72 Europe PMC632020 Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2020). No major effect of innate immune genetics on acute kidney rejection in the first 2 weeks post-transplantation. Frontiers in Pharmacology, 10, 1686-1-1686-8.
Scopus3 WoS5 Europe PMC12020 Suthers, G., & Somogyi, A. A. (2020). Pharmacogenetics of statin intolerance.. Intern Med J, 50(4), 506-507.
Scopus3 WoS2 Europe PMC12020 Somogyi, A. A., Athanasos, P., White, J., Bochner, F., & Ling, W. (2020). Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose.. Pain medicine (Malden, Mass.), 21(9), 2007-2008.
Scopus1 WoS12019 Zheng, Z., Gibson, S., Helme, R. D., Wang, Y., Lu, D. S. -C., Arnold, C., . . . Xue, C. C. L. (2019). Effects of electroacupuncture on opioid consumption in patients with chronic musculoskeletal pain: a multicenter randomized controlled trial. Pain Medicine, 20(2), 397-410.
Scopus26 WoS24 Europe PMC182019 Athanasos, P., Ling, W., Bochner, F., White, J. M., & Somogyi, A. A. (2019). Buprenorphine maintenance subjects are hyperalgesic and have no antinociceptive response to a very high morphine dose. Pain Medicine, 20(1), 119-128.
Scopus26 WoS21 Europe PMC112019 Rowsell, L., Wong, K., Yee, B., Eckert, D., Somogyi, A., Duffin, J., . . . Wang, D. (2019). The effect of acute morphine on obstructive sleep apnoea: a randomised double-blind placebo-controlled crossover trial. Thorax, 74(2), 177-184.
Scopus28 WoS26 Europe PMC102019 Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2019). Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. Pharmacogenetics and Genomics, 29(1), 9-17.
Scopus8 WoS7 Europe PMC42019 Suarez-Kurtz, G., Aklillu, E., Saito, Y., & Somogyi, A. (2019). Conference report: pharmacogenomics in special populations at WCP2018. British Journal of Clinical Pharmacology, 85(3), 467-475.
Scopus3 WoS2 Europe PMC22019 Sallustio, B. C., Noll, B. D., Coller, J. K., Tuke, J., Russ, G., & Somogyi, A. A. (2019). Relationship between allograft cyclosporin concentrations and P-glycoprotein expression in the 1st month following renal transplantation. British Journal of Clinical Pharmacology, 85(5), 1015-1020.
Scopus4 WoS3 Europe PMC12019 Gálvez Ortiz, V., Glue, P., Somogyi, A. A., Martin, D., Alonzo, A., Rodgers, A., . . . Loo, C. K. (2019). A reply to comments by Lee and colleagues on: Repeated intranasal ketamine for treatment resistant depression – the way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology, 33(2), 260-261.
2019 Chiang, D. L. C., Rice, D. A., Helsby, N. A., Somogyi, A. A., & Kluger, M. T. (2019). The Prevalence, Impact, and Risk Factors for Persistent Pain After Breast Cancer Surgery in a New Zealand Population.. Pain medicine (Malden, Mass.), 20(9), 1803-1814.
Scopus20 WoS12 Europe PMC112019 Somogyi, A. A., Barratt, D. T., Phillips, E. J., Moore, K., Ilyas, F., & Gabb, G. M. (2019). High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms. British Journal of Clinical Pharmacology, 85(9), 2163-2169.
Scopus21 WoS17 Europe PMC112019 Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2019). Is there a temporal relationship between trough whole blood tacrolimus concentration and acute rejection in the first 14 days after kidney transplantation?. Therapeutic Drug Monitoring, 41(4), 528-532.
Scopus6 WoS4 Europe PMC42018 Gálvez, V., Li, A., Huggins, C., Glue, P., Martin, D., Somogyi, A., . . . Loo, C. (2018). Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology, 32(4), 397-407.
Scopus63 WoS47 Europe PMC342018 Hu, R., Barratt, D., Coller, J., Sallustio, B., & Somogyi, A. (2018). CYP3A5*3 and ABCB1 61A>G significantly influence dose-adjusted trough blood tacrolimus concentrations in the first three months post-kidney transplantation. Basic and Clinical Pharmacology and Toxicology, 123(3), 320-326.
Scopus28 WoS17 Europe PMC142018 Tucci, J., Pumuye, P., Helsby, N., Barratt, D., Pokeya, P., Hombhanje, F., & Somogyi, A. (2018). Pharmacogenomics in Papua New Guineans: Unique profiles and implications for enhancing drug efficacy while improving drug safety. Pharmacogenetics and Genomics, 28(6), 153-164.
Scopus7 WoS5 Europe PMC62018 Licari, G., Milne, R., Somogyi, A., & Sallustio, B. (2018). Enantioselectivity in the tissue distribution of perhexiline contributes to different effects on hepatic histology and peripheral neural function in rats. Pharmacology Research and Perspectives, 6(3), e00406.
Scopus3 WoS3 Europe PMC32018 Rice, D., Kluger, M., McNair, P., Lewis, G., Somogyi, A., Borotkanics, R., . . . Walker, M. (2018). Persistent postoperative pain after total knee arthroplasty: a prospective cohort study of potential risk factors. British Journal of Anaesthesia, 121(4), 804-812.
Scopus111 WoS85 Europe PMC482018 Md Dom, Z., Coller, J., Carroll, R., Tuke, J., McWhinney, B., Somogyi, A., & Sallustio, B. (2018). Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients. British Journal of Clinical Pharmacology, 84(10), 2433-2442.
Scopus16 WoS12 Europe PMC82017 Currow, D., Watts, G., Johnson, M., McDonald, C., Miners, J., Somogyi, A., . . . Ekström, M. (2017). A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion and Morphine Sulfate (BEAMS) study protocol. BMJ Open, 7(7), e018100-1-e018100-18.
Scopus26 WoS25 Europe PMC152017 Somogyi, A. A., & Phillips, E. (2017). Genomic testing as a tool to optimise drug therapy. Australian Prescriber, 40(3), 101-104.
Scopus12 WoS92017 Barratt, D., & Somogyi, A. (2017). Role of pharmacogenetics in personalised imatinib dosing. Translational Cancer Research, 6(S10), 1541-1557.
Scopus15 WoS112017 Newcombe, D., Somogyi, A., Bochner, F., & White, J. (2017). Impaired psychomotor function and plasma methadone and levo-alpha-acetylmethadol (LAAM) concentrations in opioid-substitution patients. Experimental and Clinical Psychopharmacology, 25(3), 223-233.
2017 Mackenzie, P., Somogyi, A., & Miners, J. (2017). Advances in drug metabolism and pharmacogenetics research in Australia. Pharmacological Research, 116, 7-19.
Scopus10 WoS9 Europe PMC52017 Glue, P., Loo, C., Rodgers, A., Gálvez, V., Somogyi, A., & Mitchell, P. (2017). Comments on Cooper et al.’s review on strategies to mitigate dissociative and psychotomimetic effects from ketamine when used as a fast-acting antidepressant. World Journal of Biological Psychiatry, 18(6), 489.
Scopus2 WoS2 Europe PMC22017 Gálvez, V., Nikolin, S., Ho, K., Alonzo, A., Somogyi, A., & Loo, C. (2017). Increase in PAS-induced neuroplasticity after a treatment course of intranasal ketamine for depression. Report of three cases from a placebo-controlled trial. Comprehensive Psychiatry, 73, 31-34.
Scopus6 WoS6 Europe PMC52017 Barratt, D., Cox, H., Menelaou, A., Yeung, D., White, D., Hughes, T., & Somogyi, A. (2017). CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patients. Clinical Pharmacokinetics, 56(8), 977-985.
Scopus20 WoS17 Europe PMC132016 Somogyi, A., Sia, A., Tan, E., Coller, J., Hutchinson, M., & Barratt, D. (2016). Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain. Pain, 157(11), 2458-2466.
Scopus25 WoS18 Europe PMC112016 Loo, C., Gálvez, V., O'Keefe, E., Mitchell, P., Hadzi-Pavlovic, D., Leyden, J., . . . Glue, P. (2016). Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatrica Scandinavica, 134(1), 48-56.
Scopus171 WoS130 Europe PMC882016 Lewis, B. C., Nair, P. C., Heran, S. S., Somogyi, A. A., Bowden, J. J., Doogue, M. P., & Miners, J. O. (2016). Warfarin resistance associated with genetic polymorphism of VKORC1: Linking clinical response to molecular mechanism using computational modeling. Pharmacogenetics and Genomics, 26(1), 44-50.
Scopus14 WoS10 Europe PMC82016 Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., . . . Rodgers, A. (2016). Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. International Journal of Neuropsychopharmacology, 19(4), 1-15.
Scopus183 WoS147 Europe PMC892016 De Boer, A., Cohen, A. F., Ferro, A., Flockhart, D. A., Gilchrist, A., Isbister, G., . . . Webb, A. J. (2016). Editors' report for 2015, December 2015. British Journal of Clinical Pharmacology, 81(1), 6-7.
2016 Khan, M., Barratt, D., & Somogyi, A. (2016). Impact of CYP2C8∗3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib. Xenobiotica, 46(3), 278-287.
Scopus17 WoS14 Europe PMC82015 Currow, D., Quinn, S., Ekstrom, M., Kaasa, S., Johnson, M., Somogyi, A., & Klepstad, P. (2015). Can variability in the effect of opioids on refractory breathlessness be explained by genetic factors?. BMJ Open, 5(5), e006818-1-e006818-6.
Scopus35 WoS22 Europe PMC122015 Martin, J. H., Phillips, E., Thomas, D., & Somogyi, A. A. (2015). Adding the 'medicines' back into personalized medicine to improve cancer treatment outcomes. British Journal of Clinical Pharmacology, 80(5), 929-931.
Scopus5 WoS4 Europe PMC32015 Barratt, D., Klepstad, P., Dale, O., Kaasa, S., & Somogyi, A. (2015). Innate immune signalling genetics of pain, cognitive dysfunction and sickness symptoms in cancer pain patients treated with transdermal fentanyl. PLoS One, 10(9), e0137179-1-e0137179-13.
Scopus24 WoS19 Europe PMC92015 Somogyi, A., Coller, J., & Barratt, D. (2015). Pharmacogenetics of opioid response. Clinical Pharmacology and Therapeutics, 97(2), 125-127.
Scopus36 WoS23 Europe PMC202015 Li, Y., Jackson, K., Slon, B., Hardy, J., Franco, M., William, L., . . . Somogyi, A. (2015). CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. British Journal of Clinical Pharmacology, 80(2), 276-284.
Scopus51 WoS37 Europe PMC292015 Loke, Y. K., Somogyi, A. A., Ferro, A., & Ritter, J. M. (2015). Editors' pick 2014. British Journal of Clinical Pharmacology, 79(3), 354-356.
Scopus12015 Corrigan, F., Wu, Y., Tuke, J., Coller, J., Rice, K., Diener, K., . . . Hutchinson, M. (2015). Alcohol-induced sedation and synergistic interactions between alcohol and morphine: a key mechanistic role for Toll-like receptors and MyD88-dependent signaling. Brain, Behavior, and Immunity, 45, 245-252.
Scopus21 WoS17 Europe PMC192015 Loke, Y. K., Cohen, A. F., Ferro, A., Flockhart, D. A., Ritter, J. M., & Somogyi, A. A. (2015). Editors' report for 2014, November 2014. British Journal of Clinical Pharmacology, 79(1), 4-5.
2015 Licari, G., Somogyi, A., Milne, R., & Sallustio, B. (2015). Comparison of CYP2D metabolism and hepatotoxicity of the myocardial metabolic agent perhexiline in Sprague-Dawley and Dark Agouti rats. Xenobiotica, 45(1), 3-9.
Scopus3 WoS3 Europe PMC12014 Somogyi, A., Barratt, D., Ali, R., & Coller, J. (2014). Pharmacogenomics of methadone maintenance treatment. Pharmacogenomics, 15(7), 1007-1027.
Scopus40 WoS34 Europe PMC282014 Dooney, N., Sundararajan, K., Ramkumar, T., Somogyi, A., Upton, R., Ong, J., . . . Ludbrook, G. (2014). Pharmacokinetics of tramadol after subcutaneous administration in a critically ill population and in a healthy cohort. BMC Anesthesiology, 14(1), 33-1-33-8.
Scopus8 WoS6 Europe PMC52014 Somogyi, A. A., Lewis, L. D., Cohen, A. F., Flockhart, D. A., Ferro, A., Loke, Y. K., & Ritter, J. M. (2014). Editors' report, November 2013. British Journal of Clinical Pharmacology, 77(3), 401-402.
2014 Gálvez, V., O'Keefe, E., Cotiga, L., Leyden, J., Harper, S., Glue, P., . . . Loo, C. K. (2014). Long-lasting effects of a single subcutaneous dose of Ketamine for treating melancholic depression: A case report. Biological Psychiatry, 76(3), E1-E2.
Scopus34 WoS27 Europe PMC162014 Mulholland, C., Somogyi, A., Barratt, D., Coller, J., Hutchinson, M., Jacobson, G., . . . Sleigh, J. (2014). Association of innate immune single-nucleotide polymorphisms with the electroencephalogram during desflurane general anaesthesia. Journal of Molecular Neuroscience, 52(4), 497-506.
Scopus15 WoS11 Europe PMC92014 Md Dom, Z., Noll, B., Coller, J., Somogyi, A., Russ, G., Hesselink, D., . . . Sallustio, B. (2014). Validation of an LC-MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies. Journal of Chromatography B, 945-946, 171-177.
Scopus21 WoS19 Europe PMC72014 Gilchrist, A., Loke, Y. K., Somogyi, A. A., Cohen, A. F., & Ritter, J. M. (2014). BJCP 40th anniversary: Moving forward, looking back. British Journal of Clinical Pharmacology, 78(6), 1175-1184.
2014 Lai, R., Katalinic, N., Glue, P., Somogyi, A., Mitchell, P., Leyden, J., . . . Loo, C. (2014). Pilot dose-response trial of I.V. ketamine in treatment-resistant depression. World Journal of Biological Psychiatry, 15(7), 579-584.
Scopus78 WoS60 Europe PMC382014 Barratt, D., Bandak, B., Klepstad, P., Dale, O., Kaasa, S., Christrup, L., . . . Somogyi, A. (2014). Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenetics and Genomics, 24(4), 185-194.
Scopus47 WoS35 Europe PMC292014 Ferro, A., Loke, Y. K., Lewis, L. D., Somogyi, A., Cohen, A. F., & Ritter, J. M. (2014). Editors' pick 2013. British Journal of Clinical Pharmacology, 77(2), 228-232.
2013 Katalinic, K., Lai, R., Somogyi, A., Mitchell, P., Glue, P., & Loo, C. (2013). Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Australian and New Zealand Journal of Psychiatry, 47(8), 710-727.
Scopus100 WoS81 Europe PMC522013 Noll, B., Coller, J., Somogyi, A., Morris, R., Russ, G., Hesselink, D., . . . Sallustio, B. (2013). Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies. Therapeutic Drug Monitoring, 35(5), 617-623.
Scopus32 WoS30 Europe PMC202013 Li, Y., Coller, J., Hutchinson, M., Klein, K., Zanger, U., Stanley, N., . . . Somogyi, A. (2013). The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro. Drug Metabolism and Disposition, 41(6), 1264-1272.
Scopus40 WoS34 Europe PMC212013 Wang, D., Somogyi, A., Yee, B., Wong, K., Kaur, J., Wrigley, P., & Grunstein, R. (2013). The effects of a single mild dose of morphine on chemoreflexes and breathing in obstructive sleep apnea. Respiratory Physiology and Neurobiology, 185(3), 526-532.
Scopus42 WoS36 Europe PMC262013 Maddison, J., Somogyi, A., Jensen, B., James, H., Gentgall, M., & Rolan, P. (2013). The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype. British Journal of Clinical Pharmacology, 75(1), 208-216.
Scopus34 WoS26 Europe PMC222013 Loke, Y. K., Cohen, A. F., Ferro, A., Lewis, L. D., Ritter, J. M., & Somogyi, A. A. (2013). Editors' Report, 2012. British Journal of Clinical Pharmacology, 75(2), 301-302.
2013 Lewis, L. D., Somogyi, A., Loke, Y. K., Ferro, A., Cohen, A. F., & Ritter, J. M. (2013). Editors' pick 2012.. British journal of clinical pharmacology, 75(1), 1-6.
2012 Xue, C., Helme, R., Gibson, S., Hogg, M., Arnold, C., Somogyi, A., . . . Lu, S. (2012). Effect of electroacupuncture on opioid consumption in patients with chronic musculoskeletal pain: protocol of a randomised controlled trial. Trials, 13(1), 1-8.
Scopus14 WoS12 Europe PMC62012 Duley, J., Somogyi, A., & Martin, J. (2012). The future of thiopurine pharmacogenomics. Pharmagenomics, 13(14), 1549-1552.
Scopus14 WoS12 Europe PMC102012 Coller, J., Michalakas, J., James, H., Farquharson, A., Colvill, J., White, J., & Somogyi, A. (2012). Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients. British Journal of Clinical Pharmacology, 74(5), 835-841.
Scopus21 WoS16 Europe PMC92012 Dale, O., Somogyi, A., Li, Y., Sullivan, T., & Shavit, Y. (2012). Does intraoperative ketamine attenuate inflammatory reactivity following surgery?: a systematic review and meta-analysis. Anesthesia and Analgesia, 115(4), 934-943.
Scopus174 WoS131 Europe PMC1092012 Hutchinson, M., Northcutt, A., Hiranita, T., Wang, X., Lewis, S., Thomas, J., . . . Watkins, L. (2012). Opioid activation of toll-like receptor 4 contributes to drug reinforcement. Journal of Neuroscience, 32(33), 11187-11200.
Scopus240 WoS198 Europe PMC1752012 Barratt, D., Coller, J., Hallinan, R., Byrne, A., White, J., Foster, D., & Somogyi, A. (2012). ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmacogenomics and Personalized Medicine, 5(1), 53-62.
Scopus47 WoS42 Europe PMC252012 Wang, J., Hughes, T., Kok, C., Saunders, V., Frede, A., Groot Obbink, K., . . . White, D. (2012). Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells. British Journal of Cancer, 106(11), 1772-1778.
Scopus19 WoS18 Europe PMC152012 Wang, X., Loram, L., Ramos, K., de Jesus, A., Thomas, J., Cheng, K., . . . Yin, H. (2012). Morphine activates neuroinflammation in a manner parallel to endotoxin. Proceedings of the National Academy of Sciences of the United States of America, 109(16), 6325-6330.
Scopus378 WoS332 Europe PMC2752012 Gelston, E., Coller, J., Lopatko, O., James, H., Schmidt, H., White, J., & Somogyi, A. (2012). Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. British Journal of Clinical Pharmacology, 73(5), 786-794.
Scopus27 WoS18 Europe PMC162012 Wu, Y., Lousberg, E., Moldenhauer, L., Hayball, J., Coller, J., Rice, K., . . . Hutchinson, M. (2012). Inhibiting the TLR4-MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice. British Journal of Pharmacology, 165(5), 1319-1329.
Scopus68 WoS57 Europe PMC522012 Savvas, S., Somogyi, A., & White, J. (2012). The effect of methadone on emotional reactivity. Addiction, 107(2), 388-392.
Scopus20 WoS16 Europe PMC112012 Somogyi, A., Loke, Y., Ferro, A., Lewis, L., Cohen, A., & Ritter, J. (2012). Editors' pick 2011. British Journal of Clinical Pharmacology, 73(1), 4-8.
Scopus1 WoS12012 Somogyi, A., Lewis, L., Cohen, A., Ferro, A., Loke, Y., & Ritter, J. (2012). Editors' report, November 2011. British Journal of Clinical Pharmacology, 73(2), 159-160.
2011 Noll, B., Coller, J., Somogyi, A., Morris, R., Russ, G., Hesselink, D., . . . Sallustio, B. (2011). Measurement of Cyclosporine A in rat tissues and human kidney transplant biopsies - A method suitable for small (<1 mg) samples. Therapeutic Drug Monitoring, 33(6), 688-693.
Scopus15 WoS15 Europe PMC102011 Coller, J., Cahill, S., Edmonds, C., Farquharson, A., Longo, M., Minniti, R., . . . White, J. (2011). OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenetics and Genomics (Print Edition), 21(12), 902-905.
Scopus39 WoS33 Europe PMC262011 Huxtable, C., Roberts, L., Somogyi, A., & Macintyre, P. (2011). Acute pain management in opioid-tolerant patients: a growing challenge. Anaesthesia and Intensive Care, 39(5), 804-823.
Scopus181 WoS139 Europe PMC852011 Liu, L., Coller, J., Watkins, L., Somogyi, A., & Hutchinson, M. (2011). Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: Comparison of different mouse strains. Brain Behavior and Immunity, 25(6), 1223-1232.
Scopus54 WoS47 Europe PMC422011 Hay, J., La Vincente, S., Somogyi, A., Chapleo, C., & White, J. (2011). Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects. European Journal of Pain, 15(3), 293-298.
Scopus15 WoS12 Europe PMC92011 Wu, Y., Lousberg, E., Moldenhauer, L., Hayball, J., Robertson, S., Coller, J., . . . Hutchinson, M. (2011). Attenuation of microglial and IL-1 signaling protects mice from acute alcohol-induced sedation and/or motor impairment. Brain Behavior and Immunity, 25(Suppl 1), 155-164.
Scopus69 WoS52 Europe PMC452011 Grace, P., Hutchinson, M., Bishop, A., Somogyi, A., Mayrhofer, G., & Rolan, P. (2011). Adoptive transfer of peripheral immune cells potentiates allodynia in a graded chronic constriction injury model of neuropathic pain. Brain Behavior and Immunity, 25(3), 503-513.
Scopus24 WoS21 Europe PMC182011 Becquement, L., Alfirevic, A., Amstutz, U., Brauch, H., Jacqz-Algrain, E., Laurent-Puig, P., . . . Daly, A. (2011). Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics, 12(1), 113-124.
Scopus91 WoS70 Europe PMC522011 Loke, Y. K., Ferro, A., Lewis, L. D., Cohen, A. F., Somogyi, A., & Ritter, J. M. (2011). Editors' pick 2010. British Journal of Clinical Pharmacology, 71(1), 3-6.
2011 Licari, G., Somogyi, A. A., Milne, R. W., & Sallustio, B. C. (2011). MYOCARDIAL AND HEPATIC DISPOSITION OF THE ENANTIOMERS OF PERHEXILINE. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 109, 152. 2011 Cohen, A. F., Loke, Y. K., Ferro, A., Lewis, L. D., Somogy, A., & Ritter, J. M. (2011). Editors' report, November 2010. British Journal of Clinical Pharmacology, 71(1), 1-2.
2010 Somogyi, A., & Hardy, J. (2010). Role of pharmacogenomics in pain therapy: Focus on opioids. Cancer Forum, 34(2), 74-77.
Scopus2 WoS12010 Gordon, A., Lopatko, O., Somogyi, A., Foster, D., & White, J. (2010). (R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. British Journal of Clinical Pharmacology, 70(6), 895-902.
Scopus28 WoS22 Europe PMC122010 Grace, P., Hutchinson, M., Manavis, J., Somogyi, A., & Rolan, P. (2010). A novel animal model of graded neuropathic pain: Utility to investigate mechanisms of population heterogeneity. Journal of Neuroscience Methods, 193(1), 47-53.
Scopus44 WoS39 Europe PMC362010 Upton, R., Somogyi, A., Martinez, A., Colvill, J., & Grant, C. (2010). Pharmacokinetics and pharmacodynamics of the short-acting sedative CNS 7056 in sheep. British Journal of Anaesthesia, 105(6), 798-809.
Scopus39 WoS30 Europe PMC252010 Raungrut, P., Uchaipichat, V., Elliot, D., Janchawee, B., Somogyi, A., & Miners, J. (2010). In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. Journal of Pharmacology and Experimental Therapeutics, 334(2), 609-618.
Scopus73 WoS67 Europe PMC462010 Somogyi, A., Loke, Y., Ferro, A., Lewis, L., Cohen, A., & Ritter, J. (2010). Editors' pick 2009. British Journal of Clinical Pharmacology, 69(2), 107-110.
2010 Loke, Y., Cohen, A., Ferro, A., Lewis, L., Ritter, J., & Somogyi, A. (2010). British Journal of Clinical Pharmacology: Editors' Report, November 2009. British Journal of Clinical Pharmacology, 69(1), 1.
2010 Somogyi, A., Loke, Y., Ferro, A., Lewis, L., Cohen, A., & Ritter, J. (2010). Clinical pharmacology: A declaration of intent. British Journal of Clinical Pharmacology, 70(1), 1-2.
Scopus3 WoS3 Europe PMC32010 Hutchinson, M., Lewis, S., Coats, B., Rezvani, N., Zhang, Y., Wieseler, J., . . . Watkins, L. (2010). Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences. Neuroscience, 167(3), 880-893.
Scopus112 WoS95 Europe PMC882009 Coller, J., Beardsley, J., Bignold, J., Li, Y., Merg, F., Sullivan, T., . . . Somogyi, A. (2009). Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRMI) and opioid defendence: A meta-analysis. Pharmacogenomics and Personalized Medicine, 2(1), 9-19.
Scopus28 WoS212009 Liu, L., Hutchinson, M., White, J., Somogyi, A., & Coller, J. (2009). Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependence. Pharmacogenetics and Genomics (Print Edition), 19(11), 869-876.
Scopus41 WoS36 Europe PMC312009 Authier, N., Balayssac, D., Sautereau, M., Zangarelli, A., Courty, P., Somogyi, A., . . . Eschalier, A. (2009). Dépendance aux benzodiazépines : le syndrome de sevrage. Annales Pharmaceutiques Francaises, 67(6), 408-413.
Scopus48 Europe PMC242009 Hallinan, R., Crettol, S., Agho, K., Attia, J., Besson, J., Croquette-Krokar, M., . . . Eap, C. (2009). Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study. European Journal of Clinical Pharmacology, 65(11), 1113-1120.
Scopus16 WoS13 Europe PMC92009 Bell, J., Shearer, J., Ryan, A., Graham, R., Korompay, K., Rizzo, S., . . . Somogyi, A. (2009). The acceptability, safety, and tolerability of methadone/naloxone in a 50:1 ratio. Experimental and Clinical Psychopharmacology, 17(3), 146-153.
Scopus7 WoS6 Europe PMC72009 Ozdemir, V., Suarez-Kurtz, G., Stenne, R., Somogyi, A., Someya, T., Kayaalp, S., & Kolker, E. (2009). Risk assessment and communication tools for genotype associations with multifactorial phenotypes: The concept of "edge effect" and cultivating an ethical bridge between omics innovations and society. OMICS: A Journal of Integrative Biology, 13(1), 43-61.
Scopus58 WoS38 Europe PMC322009 Hay, J., White, J., Bochner, F., Somogyi, A., Semple, T., & Rousefell, B. (2009). Hyperalgesia in Opioid-Managed Chronic Pain and Opioid-Dependent Patients. The Journal of Pain, 10(3), 316-322.
Scopus135 WoS108 Europe PMC732009 Cohen, A., Loke, Y., Lewis, L., Schachter, M., Somogyi, A., & Ritter, J. (2009). Editors' Report, December 2008. British Journal of Clinical Pharmacology, 67(2), 151-152.
2009 Coller, J., Christrup, L., & Somogyi, A. (2009). Role of active metabolites in the use of opioids. European Journal of Clinical Pharmacology, 65(2), 121-139.
Scopus100 WoS75 Europe PMC512009 Doogue, M., Martin, J., Miners, J., & Somogyi, A. (2009). Prescribing in liver disease [1]. Australian Prescriber, 32(5), 120.
Scopus1 WoS12009 Somogyi, A. (2009). Warfarin pharmacogenetics. Australian Prescriber, 32(5), 119.
2009 Loke, Y. K., Somogyi, A., Lewis, L. D., Schachter, M., Cohen, A. F., & Ritter, J. M. (2009). Looking back: Editors' pick of 2008. British Journal of Clinical Pharmacology, 67(1), 1-4.
Scopus3 WoS3 Europe PMC32008 Hutchinson, M., Coats, B., Lewis, S., Zhang, Y., Sprunger, D., Rezvani, N., . . . Watkins, L. (2008). Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behavior and Immunity, 22(8), 1178-1189.
Scopus259 WoS227 Europe PMC1812008 Somogyi, A., Larsen, M., Abadi, R., Jittiwutikarn, J., Ali, R., & White, J. (2008). Flexible dosing of Tincture of Opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics. British Journal of Clinical Pharmacology, 66(5), 640-647.
Scopus18 WoS19 Europe PMC132008 Hay, J., White, J., Bochner, F., & Somogyi, A. (2008). Antinociceptive effects of high dose remifentanil in male methadone-maintained patients. European Journal of Pain, 12(7), 926-933.
Scopus18 WoS12 Europe PMC62008 Coller, J., Barratt, D., & Somogyi, A. (2008). Response to "No influence of ABCB1 haplotypes on methadone dosage requirement". Clinical Pharmacology & Therapeutics, 83(5), 669-670.
Scopus3 WoS22008 James, H., Gillis, D., Hissaria, P., Lester, S., Somogyi, A., Cleland, L., & Proudman, S. (2008). Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. Journal of Rheumatology, 35(4), 562-571.
Scopus56 WoS55 Europe PMC412008 Davies, B., Herbert, M., Coller, J., Somogyi, A., Milne, R., & Sallustio, B. (2008). Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. British Journal of Clinical Pharmacology, 65(3), 347-354.
Scopus8 WoS8 Europe PMC62008 La Vincente, S., White, J., Somogyi, A., Bochner, F., & Chapleo, C. (2008). Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects. Clinical Pharmacology & Therapeutics, 83(1), 144-152.
Scopus27 WoS18 Europe PMC112008 Somogyi, A. (2008). Evolution of Pharmacogenomics. Western Pharmacology Society. Proceedings, 51, 1-4.
Scopus11 Europe PMC62007 Coller, J., Joergensen, C., Foster, D., James, H., Gillis, D., Christrup, L., & Somogyi, A. (2007). Lack of influence of CYP2D6 genotype on the clearance of (R)- (S)- and racemic-methadon. International Journal of Clinical Pharmacology and Therapeutics, 45(7), 410-417.
Scopus25 WoS22 Europe PMC162007 Igel, S., Drescher, S., Murdter, T., Hofmann, U., Heinkele, G., Tegude, H., . . . Fromm, M. (2007). Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux. Clinical Pharmacokinetics, 46(9), 777-785.
Scopus62 WoS55 Europe PMC372007 Jensen, M., Foster, D., Upton, R., Grant, C., Martinez, A., & Somogyi, A. (2007). Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. Xenobiotica, 37(4), 441-457.
Scopus21 WoS18 Europe PMC172007 Inglis, S., Herbert, M., Davies, B., Coller, J., James, H., Horowitz, J., . . . Sallustio, B. (2007). Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia. Pharmacogenetics and Genomics (Print Edition), 17(5), 305-312.
Scopus6 WoS7 Europe PMC42007 Somogyi, A., Barratt, D., & Coller, J. (2007). Pharmacogenetics of opioids. Clinical Pharmacology & Therapeutics, 81(3), 429-444.
Scopus292 WoS240 Europe PMC1672007 Davies, B., Coller, J., Somogyi, A., Milne, R., & Sallustio, B. (2007). CYP2B6 CYP2D6 and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metabolism and Disposition, 35(1), 128-138.
Scopus22 WoS21 Europe PMC152006 Coller, J., Barratt, D., Dahlen, K., Loennechen, M., & Somogyi, A. (2006). ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clinical Pharmacology & Therapeutics, 80(6), 682-690.
Scopus128 WoS110 Europe PMC902006 Davies, B., Herbert, M., Coller, J., Somogyi, A., Milne, R., & Sallustio, B. (2006). Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography. Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences, 843(2), 302-309.
Scopus9 WoS10 Europe PMC42006 Villesen, H., Foster, D., Upton, R., Christrup, L., Somogyi, A., Martinez, A., & Grant, C. (2006). Blood-brain distribution of morphine-6-glucuronide in sheep. British Journal of Pharmacology, 149(6), 754-760.
Scopus3 WoS3 Europe PMC12006 Foster, D., Morton, E., Heinkele, G., Murdter, T., & Somogyi, A. (2006). Stereoselective quantification of methadone and a d(6)-labeled isotopomer using high performance liquid chromatography-atmospheric pressure chemical ionization mass-spectrometry: Application to a pharmacokinetic study in a methadone maintained subject. Therapeutic Drug Monitoring, 28(4), 559-567.
Scopus13 WoS11 Europe PMC102006 Villesen, H., Foster, D., Upton, R., Somogyi, A., Martinez, A., & Grant, C. (2006). Cerebral kinetics of oxycodone in conscious sheep. Journal of Pharmaceutical Sciences, 95(8), 1666-1676.
Scopus23 WoS20 Europe PMC202006 Mitchell, T., White, J., Somogyi, A., & Bochner, F. (2006). Switching between methadone and morphine for maintenance treatment of opioid dependence: Impact on pain sensitivity and mood status. American Journal on Addictions, 15(4), 311-315.
Scopus16 WoS13 Europe PMC122006 Mitchell, T., Dyer, K., Newcombe, D., Somogyi, A., & White, J. (2006). Fluctuations in (R,S)-methadone pharmacokinetics and response among long-term methadone maintenance patients. Addiction Biology, 11(2), 170-174.
Scopus5 WoS3 Europe PMC52006 Barratt, D., Coller, J., & Somogyi, A. (2006). Association between the DRD2 A(1) allele and response to methadone and buprenorphine maintenance treatments. American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics, 141B(4), 323-331.
Scopus46 WoS43 Europe PMC392006 Polasek, T., Elliot, D., Somogyi, A., Gillam, E., Lewis, B., & Miners, J. (2006). An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. British Journal of Clinical Pharmacology, 61(5), 570-584.
Scopus62 WoS52 Europe PMC322006 Athanasos, P., Smith, C., White, J., Somogyi, A., Bochner, F., & Ling, W. (2006). Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. Pain, 120(3), 267-275.
Scopus87 WoS66 Europe PMC532006 Davies, B., Herbert, M., Culbert, J., Pyke, S., Coller, J., Somogyi, A., . . . Sallustio, B. (2006). Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences, 832(1), 114-120.
Scopus17 WoS15 Europe PMC92006 Foster, D., Jensen, M., Upton, R., Somogyi, A., Grant, C., & Martinez, A. (2006). Blood-brain equilibration kinetics of levo-alpha-acetyl-methadol using a chronically instrumented sheep preparation. British Journal of Pharmacology, 147(2), 209-217.
Scopus3 WoS3 Europe PMC32006 Morrish, G., Foster, D., & Somogyi, A. (2006). Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids. British Journal of Clinical Pharmacology, 61(3), 326-335.
Scopus15 WoS14 Europe PMC142006 Somogyi, A. (2006). Serotonin syndrome [1]. Australian Prescriber, 29(6), 149.
2006 Barratt, D., Coller, J., & Somogyi, A. (2006). ABCB1 haplotypes determine methadone dosage requirements. ACTA PHARMACOLOGICA SINICA, 27, 229. 2006 Coller, J. K., Plevin, D., Sallustio, B. C., Somogyi, A. A., & Morris, R. G. (2006). Relationship between the ABCB1 genetic polymorphism and clinical outcomes in renal transplant patients.. ACTA PHARMACOLOGICA SINICA, 27, 229. 2005 Foster, D., Upton, R., Somogyi, A., Grant, C., & Martinez, A. (2005). The acute disposition of (R)- and (S)-methadone in brain and lung of sheep. Journal of Pharmacokinetics and Pharmacodynamics, 32(3-4), 547-570.
Scopus8 WoS7 Europe PMC52005 Hanna, J., Foster, D., Salter, A., Somogyi, A., White, J., & Bochner, F. (2005). Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects. British Journal of Clinical Pharmacology, 60(4), 404-413.
Scopus23 WoS21 Europe PMC162005 Hutchinson, M., & Somogyi, A. (2005). Characterisation of the in vitro modulation of splenocyte proliferation by non-4,5-epoxymorphinan opioids. International Immunopharmacology, 5(12), 1713-1722.
Scopus6 WoS4 Europe PMC42005 Davies, B., Coller, J., James, H., Somogyi, A., Horowitz, J., & Sallustio, B. (2005). The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia. British Journal of Clinical Pharmacology, 61(3), 321-325.
Scopus11 WoS11 Europe PMC62005 Somogyi, A. (2005). Erratum: Inside the isomers: The tale of chiral switches (Australian Prescriber (2004) 27 (47-49)). Australian Prescriber, 28(3), 58. 2005 Somogyi, A. (2005). Isomers - Correction [5]. Australian Prescriber, 28(3), 58. 2005 Somogyi, A. (2005). Inside the isomers: the tale of chiral switches(vol27, pg 47, 2004). AUSTRALIAN PRESCRIBER, 28(3), 58.
WoS12004 Pelser, D., & Somogyi, A. (2004). Inside the isomers: The tale of chiral switches [2] (multiple letters). Australian Prescriber, 27(5), 110. 2004 Somogyi, A., Bochner, F., & Foster, D. (2004). Inside the isomers: the tale of chiral switches. Australian Prescriber, 27(2), 47-49.
Scopus342004 Glaeser, H., Drescher, S., Hofmann, U., Heinkele, G., Somogyi, A., Eichelbaum, M., & Fromm, M. (2004). Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. Clinical Pharmacology & Therapeutics, 76(3), 230-238.
Scopus30 WoS26 Europe PMC172004 Athanasos, P., Morrish, G., Somogyi, A., Bochner, F., & White, J. (2004). Changes in methadone concentration, opiod effects, and opioid withdrawal during induction onto maintenance treatment. Addictive Disorders & Their Treatment, 3(3), 122-128.
2004 Hutchinson, M., & Somogyi, A. (2004). (S)-(+)methadone is more immunosuppressive than the potent analgesic (R)-(-)-methadone. International Immunopharmacology, 4(12), 1525-1530.
Scopus13 WoS12 Europe PMC102004 Hutchinson, M., La Vincente, S., & Somogyi, A. (2004). In vitro opioid induced proliferation of peripheral blood immune cells correlates with in vivo cold pressor pain tolerance in humans: a biological marker of pain tolerance. Pain, 110(3), 751-755.
Scopus13 WoS11 Europe PMC102004 Newcombe, D., Bochner, F., White, J., & Somogyi, A. (2004). Evaluation of levo-alpha-acetylmethdol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis. Drug and Alcohol Dependence, 76(1), 63-72.
Scopus24 WoS20 Europe PMC112004 Mitchell, T., Dyer, K., Newcombe, D., Salter, A., Somogyi, A., Bochner, F., & White, J. (2004). Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure. British Journal of Clinical Pharmacology, 58(6), 609-617.
Scopus43 WoS38 Europe PMC292004 Somogyi, A., Menelaou, A., & Fullston, S. (2004). CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement. Xenobiotica, 34(10), 875-887.
Scopus16 WoS11 Europe PMC92004 James, H., Coller, J., Gillis, D., Bahnisch, J., Sallustio, B., & Somogyi, A. (2004). A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis. International Journal of Clinical Pharmacology and Therapeutics, 42(12), 719-723.
Scopus19 WoS15 Europe PMC112004 Jittiwutikarn, J., Ali, R., White, J., Bochner, F., Somogyi, A., & Foster, D. (2004). Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. British Journal of Clinical Pharmacology, 58(5), 536-541.
Scopus20 WoS15 Europe PMC102004 Mitchell, T., White, J., Somogyi, A., & Bochner, F. (2004). Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction, 99(8), 940-945.
Scopus62 WoS58 Europe PMC332004 Hutchinson, M., & Somogyi, A. (2004). Relationship between 4,5-epoxymorphinan structure and in vitro modulation of cell proliferation. European Journal of Pharmacology, 494(2-3), 251-262.
Scopus10 WoS7 Europe PMC82004 Foster, D., Somogyi, A., White, J., & Bochner, F. (2004). Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. British Journal of Clinical Pharmacology, 57(6), 742-755.
Scopus70 WoS59 Europe PMC472004 Davies, B., Coller, J., James, H., Gillis, D., Somogyi, A., Horowitz, J., . . . Sallustio, B. (2004). Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline. British Journal of Clinical Pharmacology, 57(4), 456-463.
Scopus6 WoS6 Europe PMC52004 Hutchinson, M., Menelaou, A., Foster, D., Coller, J., & Somogyi, A. (2004). CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. British Journal of Clinical Pharmacology, 57(3), 287-297.
Scopus131 WoS96 Europe PMC662003 Mitchell, T., White, J., Somogyi, A., & Bochner, F. (2003). Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence. Drug and Alcohol Dependence, 72(1), 85-94.
Scopus48 WoS42 Europe PMC302003 Gross, A., Somogyi, A., & Eichelbaum, M. (2003). Stereoselective drug metabolism and drug interactions. Handbook of Experimental Pharmacology, 153, 313-339. 2003 Menelaou, A., Hutchinson, M., Quinn, I., Christensen, A., & Somogyi, A. (2003). Quantification of the O- and N-demethylated metabolites of hydrocodone and oxycodone in human liver microsomes using liquid chromatography with ultraviolet absorbance detection. Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences, 785(1), 81-88.
Scopus23 WoS19 Europe PMC122003 Sorensen, L., Sorensen, R., Miners, J., Somogyi, A., Grgurinovich, N., & Birkett, D. (2003). Polymorphic hydroxylation of perhexiline in vitro. British Journal of Clinical Pharmacology, 55(6), 635-638.
Scopus32 WoS30 Europe PMC212003 Sallustio, B., Davies, B., Coller, J., James, H., Gillis, D., & Somogyi, A. (2003). Relationship between CYP2D6 genotype and plasma OH-perhexiline/perhexiline concentration ratio in angina patients.. Therapeutic Drug Monitoring, 25(4), 519. 2002 Doverty, M., White, J., Somogyi, A., Bochner, F., Ali, R., & Ling, W. (2002). Reply to Dr. Clark's comment on Doverty et al., hyperalgesic responses in methadone maintenance patients (Pain 2001;90 : 91-96). Pain, 99(3), 609-610.
WoS12002 Glaeser, H., Drescher, S., Van der Kuip, H., Behrens, C., Geick, A., Burk, O., . . . Fromm, M. (2002). Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters. Clinical Pharmacology & Therapeutics, 71(3), 131-140.
Scopus44 WoS41 Europe PMC232002 Porter, S., Somogyi, A., & White, J. (2002). In vivo and in vitro potency studies of 6b-naltrexol, the major human metabolite of naltrexone. Addiction Biology, 7(2), 219-225.
Scopus43 WoS37 Europe PMC332002 Hutchinson, M., & Somogyi, A. (2002). Diacetylmorphine degradation to 6-monoacetylmorphine and morphine in cell culture: implications for in vitro studies. European Journal of Pharmacology, 453(1), 27-32.
Scopus18 WoS18 Europe PMC132002 Olver, I., Hercus, T., Lopez, A., Vadas, M., Somogyi, A., Doyle, I., . . . Wigley, P. (2002). A phase I study of the GM-CSF antagonist E21R. Cancer Chemotherapy and Pharmacology, 50(3), 171-178.
Scopus8 WoS8 Europe PMC62001 Doverty, M., Somogyi, A., White, J., Bochner, F., Beare, C., Menelaou, A., & Ling, W. (2001). Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain, 93(2), 155-163.
Scopus149 WoS118 Europe PMC892001 Doverty, M., White, J., Somogyi, A., Bochner, F., Ali, R., & Ling, W. (2001). Hyperalgesic responses in methadone maintenance patients. Pain, 90(01-Feb), 91-96.
Scopus268 WoS210 Europe PMC1672001 Dyer, K., White, J., Foster, D., Bochner, F., Menelaou, A., & Somogyi, A. (2001). The relationship between mood state and plasma methadone concentration in maintenance patients. Journal of Clinical Psychopharmacology, 21(1), 78-84.
Scopus64 WoS54 Europe PMC412001 Chew, M., White, J., Somogyi, A., Bochner, F., & Irvine, R. (2001). Precipitated withdrawal following codeine administration is dependent on CYP genotype. European Journal of Pharmacology, 425(3), 159-164.
Scopus8 WoS7 Europe PMC62001 von Richter, O., Greiner, B., Fromm, M., Fraser, R., Omari, T., Barclay, M., . . . Eichelbaum, M. (2001). Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clinical Pharmacology & Therapeutics, 70(3), 217-227.
Scopus98 WoS81 Europe PMC482001 Ling, M., Duncan, E., Rodgers, S., Somogyi, A., Crabb, G., Street, A., & Lloyd, J. (2001). Classification of the kinetics of factor VIII inhibitors in haemophilia A: plasma dilution studies are more discriminatory than time-course studies. British Journal of Haematology, 114(4), 861-867.
Scopus20 WoS13 Europe PMC102001 Müzes, G., Pitlik, E., Somogyi, A., & Tulassay, Z. (2001). Mild thrombocytopenia as presenting symptom of type 1 Gauchers's disease. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 39(6), 471-+.
2000 Van Crugten, J., Somogyi, A., & Nation, R. (2000). Effect of uranyl nitrate-induced renal failure on morphine disposition and antiociceptive response response in rats. Clinical and Experimental Pharmacology and Physiology, 27(1-2), 74-79.
Scopus6 WoS7 Europe PMC52000 Foster, D., Somogyi, A., & Bochner, F. (2000). Stereoselective quantification of methadone and its major oxidative metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, in human urine using high-performance liquid chromatography. Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences, 744(1), 165-176.
Scopus33 WoS32 Europe PMC122000 Porter, S., Somogyi, A., & White, J. (2000). Kinetics and inhibition of the formation of 6β-naltrexol from naltrexone in human liver cytosol. British Journal of Clinical Pharmacology, 50(5), 465-471.
Scopus56 WoS51 Europe PMC382000 Norman, R., Buchholz, M., Somogyi, A., & Amato, F. (2000). hCG core fragment is a metabolite of hCG: evidence from infusion of recombinant hCG. Journal of Endocrinology, 164, 299-305. 2000 Foster, D., Somogyi, A., Dyer, K., White, J., & Bochner, F. (2000). Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. British Journal of Clinical Pharmacology, 50(5), 427-440.
Scopus123 WoS101 Europe PMC812000 Norman, R. J., Buchholz, M. M., Somogyi, A. A., & Amato, F. (2000). hCGβ core fragment is a metabolite of hCG: Evidence from infusion of recombinant hCG. Journal of Endocrinology, 164(3), 299-305.
Scopus24 WoS18 Europe PMC131999 Greiner, B., Richter, O. V., Omari, T., Dent, J., Somogyi, A., & Eichelbaum, M. (1999). Shedded enterocytes as an ex vivo probe for gut wall metabolism. Clinical Pharmacology and Therapeutics, 65(2), 127.
Scopus1 WoS11999 Von Richter, O., Greiner, B., Omari, T., Dent, J., Somogyi, A., & Eichelbaum, M. (1999). Metabolism and transport of drugs in the human intestine studied with a perfusion catheter. Clinical Pharmacology and Therapeutics, 65(2), 127.
Scopus2 WoS11999 Coller, J., Somogyi, A., & Bochner, F. (1999). Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4. Xenobiotica, 29(10), 973-986.
Scopus33 WoS29 Europe PMC201999 Malpass, A., White, J., Irvine, R., Somogyi, A., & Bochner, F. (1999). Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and dark Agouti Rats. Pharmacology, Biochemistry and Behavior, 64(1), 29-34.
Scopus46 WoS45 Europe PMC371999 Menelaou, A., Somogyi, A., Barclay, M., & Bochner, F. (1999). Simultaneous quantification of amoxycillin and metronidazole in plasma using high-performance liquid chromatography with photodiode array detection. Journal of Chromatography B, 731(2), 261-266.
Scopus64 WoS57 Europe PMC201999 Dyer, K., Foster, D., White, J., Somogyi, A., Menelaou, A., & Bochner, F. (1999). Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clinical Pharmacology and Therapeutics, 65(6), 685-694.
Scopus126 WoS110 Europe PMC861999 Bochner, F., Somogyi, A., Christrup, L., Larsen, U., Danz, C., & Elbaek, K. (1999). Comparative pharmacokinetics of two modified-release oral morphine formulations (Reliadol and Kapanol) and an immediate-release morphine tablet (Morfin 'DAK') in healthy volunteers.. Clinical Drug Investigation, 17(1), 59-66.
Scopus8 WoS41999 Foster, D., Somogyi, A., & Bochner, F. (1999). Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4.. British Journal of Clinical Pharmacology, 47(4), 403-412.
Scopus177 WoS154 Europe PMC1141999 Coller, J., Somogyi, A., & Bochner, F. (1999). Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.. British Journal of Clinical Pharmacology, 48(2), 158-167.
Scopus42 WoS34 Europe PMC271998 Kirkwood, L., Nation, R., & Somogyi, A. (1998). Glucuronidation of dihydrocodeine by human liver microsomes and the effect of inhibitors.. Clinical and Experimental Pharmacology and Physiology, 25(3-4), 266-270.
Scopus29 WoS24 Europe PMC121998 Coller, J., Somogyi, A., & Bochner, F. (1998). Quantification of flunitrazepam's oxidative metabolites, 3-hydroxyflunitrazepam and desmethylflunitrazepam, in hepatic microsomal incubations by high performance liquid chromatography.. Journal of Chromatography B.., 719(1-2), 87-92.
Scopus12 WoS11 Europe PMC31998 Wood, M., Ashby, M., Somogyi, A., & Fleming, B. (1998). Neuropsychological and pharmacokinetic assessment of hospice inpatients receiving morphine. Journal of Pain and Symptom Management, 16(2), 112-120.
Scopus32 WoS25 Europe PMC221998 Foster, D. J. R., Somogyi, A. A., White, J., Dyer, K. R., & Bocher, F. (1998). Pharmacokinetics of (R)- and (S)-methadone in methadone maintenance population. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 358(1), R461. 1998 Coller, J. K., Somogyi, A. A., & Bochner, F. (1998). Flunitrazepam oxidative metabolism in human liver microsomes. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 358(1), R421. 1997 Kirkwood, L., Nation, R., & Somogyi, A. (1997). Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine.. British Journal of Clinical Pharmacology, 44(6), 549-555.
Scopus56 WoS40 Europe PMC231997 Coller, J., Somogyi, A., & Bochner, F. (1997). Association between CYP2C19 genotype and proguanil oxidative polymorphism.. British Journal of Clinical Pharmacology, 43(6), 659-660.
Scopus21 WoS18 Europe PMC121997 Ashby, M., Fleming, B., Wood, M., & Somogyi, A. (1997). Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. Journal of Pain and Symptom Management, 14(3), 157-167.
Scopus94 WoS65 Europe PMC561997 Kirkwood, L., Nation, R., & Somogyi, A. (1997). Determination of the dihydrocodeine metabolites, dihydromorphine and nordihydrocodeine, in hepatic microsomal incubations by high performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications, 701(1), 129-134.
Scopus7 WoS61997 Van Crugten, J., Somogyi, A., Nation, R., & Reynolds, G. (1997). The effect of old age on the disposition and antinociceptive response of morphine and morphine-6beta-glucuronide in the rat.. Pain, 71(2), 199-205.
Scopus33 WoS30 Europe PMC251997 Milne, R., McLean, C., Mather, L., Nation, R., Runciman, W., Rutten, A., & Somogyi, A. (1997). Influence of renal failure on the disposition of morphine, morphine-3-glucuronide and morphine-6-glucuronide in sheep during intravenous infusion with morphine. Journal of Pharmacology and Experimental Therapeutics, 282(2), 779-786.
Scopus25 WoS21 Europe PMC151997 Van Crugten, J., Somogyi, A., Nation, R., & Reynolds, G. (1997). Concentration-effect relationships of morphine and morphine-6beta-glucuronide in the rat. Clinical and Experimental Pharmacology and Physiology, 24(5), 359-364.
Scopus21 WoS21 Europe PMC171997 Somogyi, A. (1997). Pethidine is inappropriate for migraine. Australian Prescriber, 20(3), 71.
Scopus11996 Somogyi, A., Reinhard, H., & Bochner, F. (1996). Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism.. British Journal of Clinical Pharmacology, 41(3), 175-179.
Scopus20 WoS15 Europe PMC111996 Maddocks, I., Somogyi, A., Abbott, F., Hayball, P., & Parker, D. (1996). Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. Journal of Pain and Symptom Management, 12(3), 182-189.
Scopus166 WoS115 Europe PMC951996 Somogyi, A., Rumrich, G., Fritsch, G., & Ullrich, K. (1996). Stereospecificity in contraluminal and luminal transporters of organic cations in the proximal tubule.. Journal of Pharmacology and Experimental Therapeutics, 278(1), 31-36.
Scopus16 WoS13 Europe PMC81996 Somogyi, A., Reinhard, H., & Bochner, F. (1996). Effect of omeprazole and cimetidine on the urinary metabolic ratio of proguanil in volunteers.. European Journal of Clinical Pharmacology, 50(5), 417-419.
Scopus4 WoS4 Europe PMC31996 Milne, R., Nation, R., & Somogyi, A. (1996). The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine.. Drug Metabolism Reviews, 28(3), 345-472.
Scopus192 WoS174 Europe PMC1241996 Capon, D., Bochner, F., Kerry, N., Mikus, G., Danz, C., & Somogyi, A. (1996). The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.. Clinical Pharmacology and Therapeutics, 60(3), 295-307.
Scopus124 WoS112 Europe PMC771996 Kirkwood, L., Nation, R., Reynolds, G., Somogyi, A., & Sansom, L. (1996). Oxidative metabolism of dihydrocodeine in Dark- Agouti and Sprague-Dawley rat liver microsomes. Pharmaceutical Sciences, 2(6), 299-303.
Scopus21996 Somogyi, A. (1996). The new antidepressants. Australian Prescriber, 19(3), 60. 1995 KIRKWOOD, L. C., VENNING, M. G., NATION, R. L., REYNOLDS, G. D., SOMOGYI, A. A., & SANSOM, L. N. (1995). Comparative Activity of Dihydrocodeine and Its Metabolites in the Electrically Stimulated Guinea‐pig Isolated Ileum. Pharmacy and Pharmacology Communications, 1(12), 573-575.
Scopus61995 Somogyi, A., Bochner, F., Hetzel, D., & Williams, D. (1995). Evaluation of the intestinal absorption of erythromycin in man: Absolute bioavailability and comparison with enteric coated erythromycin. Pharmaceutical Research, 12(1), 149-154.
Scopus22 WoS23 Europe PMC141995 Milne, R., McLean, C., Mather, L., Nation, R., Runciman, W., Rutten, A., & Somogyi, A. (1995). Comparative disposition of morphine-3-glucuronide during separate intravenous infusions of morphine and morphine-3-glucuronide in sheep: Importance of the kidney. Drug Metabolism and Disposition, 23(3), 334-342.
Scopus10 WoS8 Europe PMC51994 Cleary, J. F., Mikus, G., Somogyi, A., & Bochner, F. (1994). The influence of pharmacogenetics on opioid analgesia: Studies with codeine and oxycodone in the Sprague-Dawley/dark agouti rat model. Journal of Pharmacology and Experimental Therapeutics, 271(3), 1528-1534.
Scopus69 WoS61 Europe PMC471994 Douglas, A. M., Atchison, B. A., Somogyi, A. A., & Drummer, O. H. (1994). Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism. Pharmacogenetics, 4(3), 154-158.
Scopus27 WoS26 Europe PMC111994 Kerry, N., Somogyi, A., Bochner, F., & Mikus, G. (1994). The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.. British Journal of Clinical Pharmacology, 38(3), 243-248.
Scopus103 WoS88 Europe PMC591994 BOCHNER, F., MARTIN, E. D., BURGESS, N. G., SOMOGYI, A. A., MISAN, G. M. H., ANTIC, R., . . . YEOH, E. (1994). CONTROVERSIES IN TREATMENT - HOW CAN HOSPITALS RATION DRUGS - RESPONSE. BRITISH MEDICAL JOURNAL, 308(6933), 907-908.
WoS11994 Mikus, G., Bochner, F., Eichelbaum, M., Horak, P., Somogyi, A. A., & Spector, S. (1994). Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism. Journal of Pharmacology and Experimental Therapeutics, 268(2), 546-551.
Scopus47 WoS42 Europe PMC251994 Bochner, F., Martin, E. D., Burgess, N. G., Somogyi, A. A., Misan, G. M. H., Donaldson, C., . . . Chadwick, R. (1994). Drug rationing in a teaching hospital: A method to assign priorities. British Medical Journal, 308(6933), 901-908.
Scopus13 WoS341994 Bochner, F., Martin, E. D., Burgess, N. G., Somogyi, A. A., & Misan, G. M. H. (1994). Controversies in Treatment: How can hospitals ration drugs? Drug rationing in a teaching hospital: A method to assign priorities. BMJ, 308(6933), 901.
Scopus411994 Bochner, F., Somogyi, A. A., & Chen, Z. R. (1994). Dextromethorphan metabolism in rat: Interstrain differences and the fate of individually administered oxidative metabolites. Xenobiotica, 24(6), 543-552.
Scopus20 WoS14 Europe PMC81994 SOMOGYI, A. A., SIMMONS, N., & GROSS, A. S. (1994). In‐vitro potencies of histamine H<inf>2</inf>‐receptor antagonists on tetraethylammonium uptake in rat renal brush‐border membrane vesicles. Journal of Pharmacy and Pharmacology, 46(5), 375-377.
Scopus7 WoS7 Europe PMC51994 Bochner, F., Martin, E., Burgess, N., Somogyi, A., & Misan, G. (1994). How can hospitals ration drugs? Drug rationing in a teaching hospital: a method to assign priorities. Drug Committee of the Royal Adelaide Hospital.. BMJ (Clinical research ed.), 308(6933), 901-905.
Europe PMC201994 Gross, A. S., & Somogyi, A. A. (1994). Interaction of the stereoisomers of basic drugs with the uptake of tetraethylammonium by rat renal brush-border membrane vesicles. Journal of Pharmacology and Experimental Therapeutics, 268(3), 1073-1080.
Scopus18 WoS12 Europe PMC71993 Somogyi, A. A., Nation, R. L., Olweny, C., Tsirgiotis, P., van Crugten, J., Milne, R. W., . . . Bochner, F. (1993). Plasma Concentrations and Renal Clearance of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Cancer Patients Receiving Morphine. Clinical Pharmacokinetics, 24(5), 413-420.
Scopus47 WoS47 Europe PMC281993 Milne, R. W., Sloan, P. A., McLean, C. F., Mather, L. E., Nation, R. L., Runciman, W. B., . . . Somogyi, A. A. (1993). Disposition of morphine and its 3- and 6-glucuronide metabolites during morphine infusion in the sheep. Drug Metabolism and Disposition, 21(6), 1151-1156.
Scopus23 WoS21 Europe PMC141993 Kerry, N. L., Somogyi, A. A., Mikus, G., & Bochner, F. (1993). Primary and secondary oxidative metabolism of dextromethorphan. In vitro studies with female sprague-dawley and dark agouti rat liver microsomes. Biochemical Pharmacology, 45(4), 833-839.
Scopus45 WoS44 Europe PMC281992 Milne, R., Nation, R., Somogyi, A., Bochner, F., & Griggs, W. (1992). The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive‐care patients.. British Journal of Clinical Pharmacology, 34(1), 53-59.
Scopus79 WoS70 Europe PMC491992 Somogyi, A. A., Bochner, F., & Sallustio, B. C. (1992). Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clinical Pharmacology and Therapeutics, 51(4), 379-387.
Scopus44 WoS45 Europe PMC281991 Bochner, F., Somogyi, A. A., & Wilson, K. M. (1991). Bioinequivalence of Four 100mg Oral Aspirin Formulations in Healthy Volunteers. Clinical Pharmacokinetics, 21(5), 394-399.
Scopus31 WoS31 Europe PMC171991 Mikus, G., Somogyi, A. A., Bochner, F., & Eichelbaum, M. (1991). Thebaine o-demethylation to oripavine: Genetic differences between two rat strains. Xenobiotica, 21(11), 1501-1509.
Scopus28 WoS27 Europe PMC141991 Milne, R. W., Nation, R. L., Reynolds, G. D., Somogyi, A. A., & van Crugten, J. T. (1991). High-performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites: improvements to the method and application to stability studies. Journal of Chromatography B: Biomedical Sciences and Applications, 565(1-2), 457-464.
Scopus92 WoS86 Europe PMC291991 Mikus, G., Somogyi, A. A., Bochner, F., & Elchelbaum, M. (1991). Codeine o-demethylation: Rat strain differences and the effects of inhibitors. Biochemical Pharmacology, 41(5), 757-762.
Scopus46 WoS42 Europe PMC261991 Mikus, G., Somogyi, A. A., Bochner, F., & Chen, Z. R. (1991). Polymorphic metabolism of opioid narcotic drugs: possible clinical implications. Annals of the Academy of Medicine Singapore, 20(1), 9-12.
Scopus21 Europe PMC111991 Chen, Z. R., Irvine, R. J., Somogyi, A. A., & Bochner, F. (1991). Mu receptor binding of some commonly used opioids and their metabolites. Life Sciences, 48(22), 2165-2171.
Scopus249 WoS221 Europe PMC1741991 Chen, Z., Somogyi, A., Reynolds, G., & Bochner, F. (1991). Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers.. British Journal of Clinical Pharmacology, 31(4), 381-390.
Scopus138 WoS109 Europe PMC701991 Evans, A., Nation, R., Sansom, L., Bochner, F., & Somogyi, A. (1991). Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclo‐oxygenase inhibition: relationship between inhibition of thromboxane production and the plasma unbound concentration of S(+)‐ ibuprofen.. British Journal of Clinical Pharmacology, 31(2), 131-138.
Scopus49 WoS52 Europe PMC341991 Sloan, P. A., Mather, L. E., Mclean, C. F., Rutten, A. J., Nation, R. L., Milne, R. W., . . . Somogyi, A. A. (1991). Physiological disposition of I.V. morphine in sheep. British Journal of Anaesthesia, 67(4), 378-386.
Scopus24 WoS25 Europe PMC71991 Van Crugten, J. T., Sallustio, B. C., Nation, R. L., & Somogyi, A. A. (1991). Renal tubular transport of morphine, morphine-6-glucuronide, and morphine-3-glucuronide in the isolated perfused rat kidney. Drug Metabolism and Disposition, 19(6), 1087-1092.
Scopus43 WoS41 Europe PMC221991 Muirhead, M. R., & Somogyi, A. A. (1991). Effect of H<inf>2</inf> antagonists on the differential secretion of triamterene and its sulfate conjugate metabolite by the isolated perfused rat kidney. Drug Metabolism and Disposition, 19(2), 312-316.
Scopus15 WoS12 Europe PMC91991 Somogyi, A., Bochner, F., & Chen, Z. R. (1991). Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. European Journal of Clinical Pharmacology, 41(4), 379-382.
Scopus13 WoS11 Europe PMC21990 Somogyi, A., Siebert, D., & Bochner, F. (1990). Determination of endogenous concentrations of N<sup>1</sup>-methylnicotinamide in human plasma and urine by high-performance liquid chromatography. Analytical Biochemistry, 187(1), 160-165.
Scopus19 WoS19 Europe PMC121990 Chen, Z. R., Somogyi, A., & Bochner, F. (1990). Dextromethorphan: pharmacogenetics, and a pilot study to determine its disposition and antitussive effect in poor and extensive metabolisers. European Journal of Pharmacology, 183(4), 1573-1574.
Scopus4 WoS21990 Somogyi, A., Sallustio, B., & Bochner, F. (1990). Stereoselective reduction of pindolol enantiomer renal clearance by cimetidine in man. European Journal of Pharmacology, 183(4), 1157-1158.
1990 Zhao Rong Chen., Irvine, R. J., Bochner, F., & Somogyi, A. A. (1990). Morphine formation from codeine in rat brain: A possible mechanism of codeine analgesia. Life Sciences, 46(15), 1067-1074.
Scopus68 WoS61 Europe PMC411990 Wilson, K. M., Siebert, D. M., Duncan, E. M., Somogyi, A. A., Lloyd, J. V., & Bochner, F. (1990). Effect of aspirin infusions on platelet function in humans. Clinical Science, 79(1), 37-42.
Scopus9 WoS11 Europe PMC71990 Evans, A. M., Nation, R. L., Sansom, L. N., Bochner, F., & Somogyi, A. A. (1990). The relationship between the pharmacokinetics of ibuprofen enantiomers and the dose of racemic ibuprofen in humans. Biopharmaceutics & Drug Disposition, 11(6), 507-518.
Scopus46 WoS48 Europe PMC231990 Chen, Z. R., Somogyi, A. A., & Bochner, F. (1990). Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Therapeutic Drug Monitoring, 12(1), 97-104.
Scopus127 WoS125 Europe PMC641990 Misan, G. M. H., Martin, E. D., Smith, E. R., Somogyi, A. A., Bartholomeusz, R. C. A., & Bochner, F. (1990). Drug utilization review in a teaching hospital: experience with vancomycin. European Journal of Clinical Pharmacology, 39(5), 457-461.
Scopus25 WoS24 Europe PMC161990 SOMOGYI, A. A., WATSONABADY, J. A., & MANDEL, F. S. (1990). ATTITUDES TOWARD THE CARE OF PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME - A SURVEY OF COMMUNITY INTERNISTS. ARCHIVES OF INTERNAL MEDICINE, 150(1), 50-53.
WoS91990 Somogyi, A., Hewson, D., Muirhead, M., & Bochner, F. (1990). Amiloride disposition in geriatric patients: importance of renal function.. British Journal of Clinical Pharmacology, 29(1), 1-8.
Scopus23 WoS18 Europe PMC111989 CHEN, Z. R., REYNOLDS, G., BOCHNER, F., & SOMOGYI, A. (1989). DIRECT DETERMINATION OF CODEINE-6-GLUCURONIDE IN PLASMA AND URINE USING SOLID-PHASE EXTRACTION AND HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION. JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 493(2), 313-324.
WoS181989 Muirhead, M. R., Somogyi, A. A., Lloyd, C., & Bochner, F. (1989). Deconjugation of p-hydroxytriamterene sulphate in the rat. Xenobiotica, 19(6), 655-660.
Scopus5 WoS3 Europe PMC41989 Evans, A. M., Nation, R. L., Sansom, L. N., Bochner, F., & Somogyi, A. A. (1989). Stereoselective plasma protein binding of ibuprofen enantiomers. European Journal of Clinical Pharmacology, 36(3), 283-290.
Scopus93 WoS90 Europe PMC631989 Somogyi, A. A., Hovens, C. M., Muirhead, M. R., & Bochner, F. (1989). Renal tubular secretion of amiloride and its inhibition by cimetidine in humans and in an animal model. Drug Metabolism and Disposition, 17(2), 190-196.
Scopus36 WoS34 Europe PMC141989 Chen, Z. R., Bochner, F., & Somogyi, A. (1989). Simultaneous determination of codeine, norcodeine and morphine in biological fluids by high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B: Biomedical Sciences and Applications, 491(C), 367-378.
Scopus39 WoS34 Europe PMC91989 Rong Chen, Z., Reynolds, G., Bochner, F., & Somogyi, A. (1989). Direct determination of codeine-6-glucuronide in plasma and urine using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B: Biomedical Sciences and Applications, 493(C), 313-324.
Scopus21 Europe PMC61988 Chen, Z., Bochner, F., & Somogyi, A. (1988). Pharmacokinetics of pholcodine in healthy volunteers: single and chronic dosing studies.. British Journal of Clinical Pharmacology, 26(4), 445-453.
Scopus42 WoS25 Europe PMC131988 Somogyi, A., Keal, J., & Bochner, F. (1988). Sensitive high-performance liquid chromatographic assay for determination of amiloride in biologic fluids using an ion-pair extraction method. Therapeutic Drug Monitoring, 10(4), 463-468.
Scopus12 WoS11 Europe PMC31988 Muirhead, M., Bochner, F., & Somogyi, A. (1988). Pharmacokinetic drug interactions between triamterene and ranitidine in humans: Alterations in renal and hepatic clearances and gastrointestinal absorption. Journal of Pharmacology and Experimental Therapeutics, 244(2), 734-739.
Scopus37 WoS39 Europe PMC241988 Evans, A., Nation, R., Sansom, L., Bochner, F., & Somogyi, A. (1988). Stereoselective drug disposition: potential for misinterpretation of drug disposition data.. British Journal of Clinical Pharmacology, 26(6), 771-780.
Scopus57 WoS52 Europe PMC441988 Chen, Z. R., Siebert, D. M., Somogyi, A. A., & Bochner, F. (1988). Determination of pholcodine in biological fluids by high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B: Biomedical Sciences and Applications, 424(C), 170-176.
Scopus14 WoS10 Europe PMC41988 Somogyi, A. A., & Bochner, F. (1988). The absorption and disposition of enoxacin in healthy subjects. Journal of Clinical Pharmacology, 28(8), 707-713.
Scopus14 WoS12 Europe PMC111988 Chen, Z. R., Somogyi, A. A., & Bochner, F. (1988). POLYMORPHIC O-DEMETHYLATION OF CODEINE. The Lancet, 332(8616), 914-915.
Scopus110 WoS98 Europe PMC591987 Somogyi, A. A., Bochner, F., Keal, J. A., Rolan, P. E., & Smith, M. (1987). Effect of food on enoxacin absorption. Antimicrobial Agents and Chemotherapy, 31(4), 638-639.
Scopus25 WoS28 Europe PMC261987 Somogyi, A. (1987). New insights into the renal secretion of drugs. Trends in Pharmacological Sciences, 8(9), 354-357.
Scopus31 WoS521987 Somogyi, A., Muirhead, M., Kirch, W., Ohnhaus, E. E., & Pabst, J. (1987). Interaction of cimetidine with bisoprolol. European Journal of Clinical Pharmacology, 33(1), 109-110.
Scopus1 WoS11987 Somogyi, A., & Muirhead, M. (1987). Pharmacokinetic Interactions of Cimetidine 1987. Clinical Pharmacokinetics, 12(5), 321-366.
Scopus179 WoS194 Europe PMC1161987 Heinzow, B. G. J., Somogyi, A., & McLean, A. J. (1987). Influence of hydralazine on the pharmacokinetics of orally administered d-propranolol and lidocaine and conscious dogs. Archives Internationales de Pharmacodynamie et de Therapie, 286(1), 5-14.
Scopus6 WoS6 Europe PMC31987 Somogyi, A., Stockley, C., Keal, J., Rolan, P., & Bochner, F. (1987). Reduction of metformin renal tubular secretion by cimetidine in man.. British Journal of Clinical Pharmacology, 23(5), 545-551.
Scopus269 WoS222 Europe PMC1601986 Rolan, P., & Somogyi, A. (1986). Prescribing for the patient with renal disease. Medical Journal of Australia, 145(5), 210-215.
WoS11986 Keal, J., & Somogyi, A. (1986). Rapid and sensitive high-performance liquid chromatographic assay for metformin in plasma and urine using ion-pair extraction techniques. Journal of Chromatography B: Biomedical Sciences and Applications, 378(C), 503-508.
Scopus50 WoS47 Europe PMC111986 Somogyi, A., & Rolan, P. (1986). Drug disposition and dosing in hepatic disease. Medical Journal of Australia, 145(6), 284-289.
Scopus1 WoS2 Europe PMC11986 Stockley, C., Keal, J., Rolan, P., Bochner, F., & Somogyi, A. (1986). Lack of inhibition of tolbutamide hydroxylation by cimetidine in man. European Journal of Clinical Pharmacology, 31(2), 235-237.
Scopus16 WoS17 Europe PMC91986 Van Crugten, J., Bochner, F., Keal, J., & Somogyi, A. (1986). Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. Journal of Pharmacology and Experimental Therapeutics, 236(2), 481-487.
Scopus83 WoS79 Europe PMC391986 Keal, J., Stockley, C., & Somogyi, A. (1986). Simultaneous determination of tolbutamide and its hydroxy and carboxy metabolites in plasma and urine by high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications, 378(C), 237-241.
Scopus14 WoS14 Europe PMC61986 MARLIN, G. E., BRAUDE, P. D., WHELAN, A. J., & SOMOGYI, A. A. (1986). DISTRIBUTION OF ENOXACIN BETWEEN PLASMA AND BRONCHIAL-MUCOSA. AMERICAN REVIEW OF RESPIRATORY DISEASE, 133(4), A70. 1986 Marlin, G. E., Braude, P. D., Whelan, A. J., & Somogyi, A. A. (1986). Penetration of enoxacin into human bronchial mucosa. American Review of Respiratory Disease, 134(6), 1209-1212.
Scopus25 WoS29 Europe PMC131986 Muirhead, M. K., somogyi, A. A., Rolan, P. E., & Bochner, F. (1986). Effect of cimetidine on renal and hepatic drug elimination: Studies with triamterene. Clinical Pharmacology and Therapeutics, 40(4), 400-407.
Scopus44 WoS54 Europe PMC271985 Somogyi, A., Becker, M., & Gugler, R. (1985). Cimetidine pharmacokinetics and dosage requirements in children. European Journal of Pediatrics, 144(1), 72-76.
Scopus28 WoS19 Europe PMC151985 Somogyi, A., & Gugler, R. (1985). Effect of variations in urine pH and flow rate on cimetidine renal disposition in man. Biopharmaceutics & Drug Disposition, 6(3), 345-349.
Scopus4 WoS5 Europe PMC21985 Somogyi, A., & Bochner, F. (1985). Ranitidine and procainamide absorption [letter]. British Journal of Clinical Pharmacology, 20(2), 182-183.
Scopus3 WoS2 Europe PMC31985 Gugler, R., Jensen, J. C., Rohner, H. G., Reimnitz, P., & Somogyi, A. (1985). Factors predicting the therapeutic outcome of duodenal ulcer treatment with H<inf>2</inf>-receptor antagonists. Klinische Wochenschrift, 63(22), 1152-1159.
Scopus8 WoS13 Europe PMC51984 Somogyi, A., & Bochner, F. (1984). Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man.. British Journal of Clinical Pharmacology, 18(2), 175-181.
Scopus68 WoS64 Europe PMC421984 Eichelbaum, M., & Somogyi, A. (1984). Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing - Studies with deuterated verapamil. European Journal of Clinical Pharmacology, 26(1), 47-53.
Scopus50 WoS67 Europe PMC321984 Somogyi, A. A., Kong, C. B., Gurr, F. W., Sabto, J., Spicer, W. J., & Mclean, A. J. (1984). Metronidazole pharmacokinetics in patients with acute renal failure. Journal of Antimicrobial Chemotherapy, 13(2), 183-189.
Scopus16 WoS8 Europe PMC51983 Somogyi, A., McLean, A., & Heinzow, B. (1983). Cimetidine-procainamide pharmacokinetic interaction in man: Evidence of competition for tubular secretion of basic drugs. European Journal of Clinical Pharmacology, 25(3), 339-345.
Scopus152 WoS151 Europe PMC861983 Somogyi, A., & Gugler, R. (1983). Clinical Pharmacokinetics of Cimetidine. Clinical Pharmacokinetics, 8(6), 463-495.
Scopus148 WoS161 Europe PMC971983 Somogyi, A., Kong, C., Sabto, J., Gurr, F. W., Spicer, W. J., & McLean, A. J. (1983). Disposition and removal of metronidazole in patients undergoing haemodialysis. European Journal of Clinical Pharmacology, 25(5), 683-687.
Scopus8 WoS7 Europe PMC61983 Mclean, A., Somogyi, A., Ioannides-Demos, L., Tong, N., & Spicer, J. (1983). SUCCESSFUL SUBSTITUTION OF RECTAL METRONIDAZOLE ADMINISTRATION FOR INTRAVENOUS USE. The Lancet, 321(8314-8315), 41-43.
Scopus9 WoS12 Europe PMC51983 Rolan, P. E., Somogyi, A. A., Drew, M. J. R., Cobain, W. G., South, D., & Bochner, F. (1983). Phenytoin intoxication during treatment with parenteral miconazole. British Medical Journal, 287(6407), 1760.
Scopus25 WoS24 Europe PMC131983 Ioannides Demos, L. L., Tong, N., & Somogyi, A. A. (1983). Clinical pharmacy monitoring and utilisation of enteral and parenteral metronidazole in a general hospital. Australian Journal of Hospital Pharmacy, 13(1), 4-7.
Scopus11983 Morgan, D. J., Ching, M. S., Raymond, K., Bury, R. W., Mashford, M. L., Kong, B., . . . Somogyi, A. A. (1983). Elimination of amphotericin B in impaired renal function. Clinical Pharmacology and Therapeutics, 34(2), 248-253.
Scopus27 WoS26 Europe PMC181982 Somogyi, A., & Heinzow, B. (1982). Cimetidine Reduces Procainamide Elimination. New England Journal of Medicine, 307(17), 1080.
Scopus26 WoS30 Europe PMC111982 Gugler, R., Rohner, H. G., & Somogyi, A. A. (1982). Treatment failure of cimetidine in duodenal ulcer. Deutsche Medizinische Wochenschrift, 107(27), 1054-1057.
Scopus7 WoS12 Europe PMC61982 EICHELBAUM, M., OCHS, H. R., ROBERTS, G., & SOMOGYI, A. (1982). PHARMACOKINETICS AND METABOLISM OF ANTIPYRINE (PHENAZONE) AFTER INTRAVENOUS AND ORAL-ADMINISTRATION. ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 32-1(5), 575-578.
WoS441982 Gugler, R., Muller‐Liebenau, B., & Somogyi, A. (1982). Altered disposition and availability of cimetidine in liver cirrhotic patients.. British Journal of Clinical Pharmacology, 14(3), 421-430.
Scopus16 WoS17 Europe PMC131982 Somogyi, A., Gugler, R., & Muller Liebenau, B. (1982). Influence of liver cirrhosis on the pharmacokinetics, bioavailability and metabolism of cimetidine. Clinical and Experimental Pharmacology and Physiology, 9(4), 400. 1982 Eichelbaum, M., Ochs, H. R., Roberts, G., & somogyi, A. (1982). Pharmacokinetics and metabolism of antipyrine (Phenazone) after intravenous and oral administration. Arzneimittel-Forschung/Drug Research, 32(5), 575-578.
Scopus40 Europe PMC141982 KUSZYNSKI, C., SOMOGYI, A., & LANGENBACH, R. (1982). MODIFICATION OF BENZO[ALPHA]PYRENE-INDUCED TRANSFORMATION OF C3H-10T1/2 CELLS BY PREGNENOLONE-16-ALPHA-CARBONITRILE AND DEXAMETHASONE. CANCER LETTERS, 15(3), 215-221.
WoS21982 Somogyi, A., & Gugler, R. (1982). Drug Interactions with Cimetidine. Clinical Pharmacokinetics, 7(1), 23-41.
Scopus220 WoS290 Europe PMC1681982 Somogyi, A., Eichelbaum, M., & Gugler, R. (1982). Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data. European Journal of Clinical Pharmacology, 22(1), 85-90.
Scopus17 WoS19 Europe PMC71982 Gugler, R., Rohner, H. G., & Somogyi, A. A. (1982). Gastric acid inhibition and oxmetidine kinetics in duodenal ulcer. Clinical Pharmacology and Therapeutics, 31(4), 501-507.
Scopus3 WoS12 Europe PMC21982 Eichelbaum, M., von Unruh, G. E., & Somogyi, A. (1982). Application of Stable Labelled Drugs in Clinical Pharmacokinetic Investigations. Clinical Pharmacokinetics, 7(6), 490-507.
Scopus55 WoS49 Europe PMC301981 Ramzan, M. I., Somogyi, A. A., Walker, J. S., Shanks, C. A., & Triggs, E. J. (1981). Clinical Pharmacokinetics of the Non-depolarising Muscle Relaxants. Clinical Pharmacokinetics, 6(1), 25-60.
Scopus22 WoS20 Europe PMC71981 Gugler, R., Fuchs, G., Dieckmann, M., & Somogyi, A. A. (1981). Cimetidine plasma concentration-response relationships. Clinical Pharmacology and Therapeutics, 29(6), 744-748.
Scopus42 WoS56 Europe PMC321981 Eichelbaum, M., Somogyi, A., von Unruh, G. E., & Dengler, H. J. (1981). Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. European Journal of Clinical Pharmacology, 19(2), 133-137.
Scopus99 WoS109 Europe PMC631981 Gugler, R., Brand, M., & Somogyi, A. (1981). Impaired cimetidine absorption due to antacids and metoclopramide. European Journal of Clinical Pharmacology, 20(3), 225-228.
Scopus58 WoS70 Europe PMC471981 Somogyi, A., Thielscher, S., & Gugler, R. (1981). Influence of phenobarbital treatment on cimetidine kinetics. European Journal of Clinical Pharmacology, 19(5), 343-347.
Scopus24 WoS25 Europe PMC191981 Eichelbaum, M., Dengler, H. J., Somogyi, A., & von Unruh, G. E. (1981). Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination - Studies of the relative bioavailability of verapamil tablets. European Journal of Clinical Pharmacology, 19(2), 127-131.
Scopus67 WoS76 Europe PMC361981 KUSZYNSKI, C., SOMOGYI, A., NESNOW, S., & LANGENBACH, R. (1981). INHIBITION OF BENZO(A)PYRENE-INDUCED TRANSFORMATION OF C3H-1OT1-2 CELLS BY ALLYLISOPROPYLACETAMIDE AND ISOPROPYLVALERAMIDE. CANCER RESEARCH, 41(5), 1893-1897.
WoS81981 Ioannides, L., Somogyi, A., Spicer, J., Heinzow, B., Tong, N., Franklin, C., & Mclean, A. (1981). Rectal Administration of Metronidazole Provides Therapeutic Plasma Levels in Postoperative Patients. New England Journal of Medicine, 305(26), 1569-1570.
Scopus30 WoS40 Europe PMC211981 Eichelbaum, M., & Somogyi, A. (1981). Pharmacokinetics and bioavailability of verapamil during chronic oral dosage. Naunyn-Schmiedeberg's Archives of Pharmacology, 316(Suppl.), 292.
Scopus21981 Somogyi, A., & Gugler, R. (1981). Clinical pharmacokinetics of cimetidine with observations on the plasma concentration-response curve. Methods and Findings in Experimental and Clinical Pharmacology, 3(Suppl. 1), S83-S87.
Scopus6 WoS4 Europe PMC31981 Somogyi, A., Albrecht, M., Kliems, G., Schafer, K., & Eichelbaum, M. (1981). Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.. British Journal of Clinical Pharmacology, 12(1), 51-60.
Scopus107 WoS118 Europe PMC701981 Gugler, R., Somogyi, A., & Bergmann, K. (1981). The biliary excretion of histamine H<inf>2</inf>-receptor antagonists cimetidine and oxmetidine. Clinical Pharmacology and Therapeutics, 29(2), 249-250.
Scopus14 WoS191980 Eichelbaum, M., Albrecht, M., Kliems, G., Schafer, K., & Somogyi, A. (1980). Influence of meso‐caval shunt surgery on verapamil kinetics, bioavailability and response.. British Journal of Clinical Pharmacology, 10(5), 527-530.
Scopus28 WoS35 Europe PMC211980 Shanks, C. A., Somogyi, A. A., Ramzan, M. I., & Triggs, E. J. (1980). Tubocurarine and pancuronium: A pharmacokinetic view. Anaesthesia and Intensive Care, 8(1), 4-12.
Scopus1 WoS5 Europe PMC21980 Somogyi, A. (1980). Pancuronium plasma clearance and age. British Journal of Anaesthesia, 52(3), 360.
WoS4 Europe PMC11980 Somogyi, A., & Gugler, R. (1980). Absolute bioavailability of theophylline. Fortschritte der Medizin, 98(43), 1707-1710.
Scopus1 WoS4 Europe PMC11980 Somogyi, A., & Gugler, R. (1980). Gastric acid inhibitory effect and pharmacokinetics of a new histamine-H2-antagonist, 92 994. Hepato-Gastroenterology, 27(SUPPL.). 1980 Gugler, R., Wolf, H., Kliems, G., & Somogyi, A. (1980). Bioavailability of cimetidine after partial gastrectomy. Munchener Medizinische Wochenschrift, 122(39), 1337-1340.
Scopus4 WoS4 Europe PMC31980 Somogyi, A., Rohner, H. G., & Gugler, R. (1980). Pharmacokinetics and Bioavailability of Cimetidine in Gastric and Duodenal Ulcer Patients. Clinical Pharmacokinetics, 5(1), 84-94.
Scopus80 WoS108 Europe PMC581980 Eichelbaum, M., Birkel, P., Grube, E., Gütgemann, U., & Somogyi, A. (1980). Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single i.v. and oral administration and during chronic treatment. Klinische Wochenschrift, 58(18), 919-925.
Scopus88 WoS126 Europe PMC621979 Shanks, C. A., Somogyi, A. A., & Triggs, E. J. (1979). Dose-response and plasma concentration-response relationships of pancuronium in man. Anesthesiology, 51(2), 111-118.
Scopus20 WoS53 Europe PMC171979 Gugler, R., Djowinarto, H., Kliems, G., & Somogyi, A. (1979). Cimetidine kinetics in patients after Billroth I and II gastric resections. Zeitschrift fur Gastroenterologie, 17(9), 640-641. 1979 Gugler, R., & Somogyi, A. (1979). Reduced Cimetidine Clearance with Age. New England Journal of Medicine, 301(8), 435.
Scopus7 Europe PMC41979 Somogyi, A., & Gugler, R. (1979). Cimetidine excretion into breast milk.. British Journal of Clinical Pharmacology, 7(6), 627-629.
Scopus72 WoS67 Europe PMC401979 Somogyi, A., Gugler, R., Redolfi, A., Borgogelli, E., & Lodola, E. (1979). Increased bioavailability of cimetidine with age? - Letter to the editor concerning the article "blood level of cimetidine in relation to age" by A. Redolfi, E. Borgogelli, and E. Lodola Eur. J. Clin. Pharmacol. 15, 257-261 (1979). European Journal of Clinical Pharmacology, 16(6), 431-433.
Scopus1 WoS4 Europe PMC41978 Shanks, C., Somogyi, A., & Triggs, E. (1978). Plasma levels of pancuronium as a determinant of neuromuscular response in man [proceedings]. British Journal of Clinical Pharmacology, 6(5), 452P-453P.
1978 Somogyi, A. A., Triggs, E. J., & Shanks, C. A. (1978). Pancuronium disposition and response. Clinical and Experimental Pharmacology and Physiology, 5(3), 250.
WoS21978 Somogyi, A. A., Shanks, C. A., & Triggs, E. J. (1978). Combined I.V. Bolus and infusion of pancuronium bromide. British Journal of Anaesthesia, 50(6), 575-582.
Scopus10 WoS18 Europe PMC71978 Shanks, C. A., Somogyi, A. A., & Triggs, E. J. (1978). Plasma concentrations of pancuronium during predetermined intensities of neuromuscular blockade. British Journal of Anaesthesia, 50(3), 235-239.
Scopus8 WoS15 Europe PMC61977 Somogyi, A. A., Triggs, E. J., & Shanks, C. A. (1977). Disposition kinetics of pancuronium bromide in patients with total biliary obstruction. British Journal of Anaesthesia, 49(11), 1103-1108.
Scopus29 WoS64 Europe PMC201977 Shanks, C. A., Somogyi, A. A., & Triggs, E. J. (1977). Plasma pancuronium concentrations during predetermined intensities of neuromuscular blockade. Anaesthesia and Intensive Care, 5(4), 395. 1977 Shanks, C., Somogyi, A., & Triggs, E. (1977). Neuromuscular responses and blood concentrations of pancuronium. Anaesthesia and Intensive Care, 5(1), 81. 1977 Somogyi, A. A., Shanks, C. A., & Triggs, E. J. (1977). The effect of renal failure on the disposition and neuromuscular blocking action of pancuronium bromide. European Journal of Clinical Pharmacology, 12(1), 23-29.
Scopus31 WoS45 Europe PMC171976 Somogyi, A. A., Shanks, C. A., & Triggs, E. J. (1976). Clinical pharmacokinetics of pancuronium bromide. European Journal of Clinical Pharmacology, 10(5), 367-372.
Scopus18 WoS47 Europe PMC151976 SOMOGYI, A., MALICK, L. E., LANGENBACH, R., & SALLACH, K. (1976). CONTEMPORARY ANIMAL NUTRITION AND ITS POTENTIAL HAZARDS TO HUMAN HEALTH. ZENTRALBLATT FUR BAKTERIOLOGIE MIKROBIOLOGIE UND HYGIENE SERIE B-UMWELTHYGIENE KRANKENHAUSHYGIENE ARBEITSHYGIENE PRAVENTIVE MEDIZIN, 163(1-4), 153-172. 1975 SOMOGYI, A., LEVIN, W., BANERJEE, S., KUNTZMAN, R., & CONNEY, A. H. (1975). INHIBITION OF ACUTE TOXICITY AND ADRENOCORTICOLYTIC EFFECT OF 7,12-DIMETHYLBENZ(A)ANTHRACENE BY ISOPROPYLVALERAMIDE AND ALLYLISOPROPYLACETAMIDE IN RAT. CANCER RESEARCH, 35(9), 2500-2505.
WoS51973 CONNEY, A. H., LU, A. Y. H., LEVIN, W., SOMOGYI, A., WEST, S., JACOBSON, M., . . . KUNTZMAN, R. (1973). EFFECT OF ENZYME INDUCERS ON SUBSTRATE-SPECIFICITY OF CYTOCHROME P-450S. DRUG METABOLISM AND DISPOSITION, 1(1), 199-210.
WoS611972 LU, A. Y. H., WEST, S., SOMOGYI, A., CONNEY, A. H., & KUNTZMAN, R. (1972). PREGNENOLONE-16ALPHA-CARBONITRILE - NEW TYPE OF INDUCER OF DRUG-METABOLIZING ENZYMES. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 152(2), 457-&.
WoS2251971 SOMOGYI, A., KOVACS, K., SOLYMOSS, B., KUNTZMAN, R., & CONNEY, A. H. (1971). SUPPRESSION OF 7,12-DIMETHYLBENZ[ALPHA]ANTHRACENE-PRODUCED ADRENAL NCROSIS BY STEROIDS CAPABLE OF INDUCING ARYL HYDROCARBON HYDROXYLASE. LIFE SCIENCES PT-2 BIOCHEMISTRY GENERAL AND MOLECULAR BIOLOGY, 10(22), 1261-&.
WoS431970 SOMOGYI, A., & KOVACS, K. (1970). DIMETHYL SULFOXIDE, A CONVENIENT SOLVENT OF 7,12-DIMETHYLBENZ(A)ANTHRACENE FOR INTRAVENOUS INJECTION. CANCER RESEARCH, 30(7), 1958-&.
WoS11 -
Books
-
Book Chapters
Year Citation 2016 Coller, J., Barratt, D., & Somogyi, A. (2016). Clinically significant interactions with anti-addiction agents. In M. Jann, S. Penzak, & L. Cohen (Eds.), Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents (pp. 565-577). Switzerland: Spinger.
DOI2016 Martin, J., & Somogyi, A. (2016). Issues of Pharmacogenomics in Monitoring Warfarin Therapy. In W. Clarke, & A. Dasgupta (Eds.), Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, Physiological Conditions, and Pharmacogenomics (1 ed., pp. 261-277). Amsterdam, Netherlands: Elsevier.
DOI2012 Martin, J., & Somogyi, A. (2012). Pharmacogenomics and Warfarin Therapy. In Therapeutic Drug Monitoring: Newer Drugs and Biomarkers (pp. 161-173).
DOI2012 Martin, J., & Somogyi, A. (2012). Pharmacogenomics and Warfarin therapy. In A. Dastupta (Ed.), Therapeutic Drug Monitoring: Newer Drugs and Biomarkers (1 ed., pp. 161-173). United States: Elsevier.
DOI2012 Somogyi, A., & Coller, J. (2012). Drugs against acute and chronic pain. In P. Anzenbacher, & U. Zanger (Eds.), Metabolism of Drugs and Other Xenobiotics (1 ed., pp. 403-428). Germany: Wiley.
DOI Scopus32010 Somogyi, A. (2010). Pharmacogenetics in palliative care. In W. Newman (Ed.), Pharmacogenetics: making Cancer treatment safer and more effective (pp. 115-125). Dordrecht: Springer.
DOI2009 Gordon, A., Hutchinson, M., La Vincente, S., Mitchell, T., Morrish, G., Newcombe, D., . . . White, J. (2009). Pharmacology of opioid agonists and antagonists. In R. Mattick, R. Ali, & N. Lintzeris (Eds.), Pharmacotherapies for the Treatment of Opioid Dependence: Efficacy, Cost-Effectiveness and Implementation Guidelines (pp. 15-53). New York, USA: Informa. 2008 Somogyi, A., & Coller, J. (2008). Pharmacogenomics and Pharmacogenetics. In An Integrated Compendium of Twenty Encyclopedias (pp. 1-20). United Kingdom: Eolss Publishers. 2002 Gross, A. S., Somogyi, A., & Eichelbaum, M. (2002). Stereoselective Drug Metabolism and Drug Interactions. In M. Eichelbaum, B. Testa, & A. Somogyi (Eds.), Handbook of Experimental Pharmacology (Vol. 153, pp. 313-339). 2002 Gross, A. S., Somogyi, A., & Eichelbaum, M. (2002). Stereoselective Drug Metabolism and Drug Interactions. In M. Eichelbaum, B. Testa, & A. Somogyi (Eds.), Handbook of Experimental Pharmacology (Vol. 153, pp. 313-339). 1998 Somogyi, A. A. (1998). Clinical pharmacokinetics and drug dosing. In T. M. Brody, J. Larner, K. P. Minneman, & H. C. Neu (Eds.), Human Pharmacology : Molecular to Clinical (3rd ed.). 1996 Somogyi, A. A. (1996). Drug interactions involving renal excretory mechanisms in Mechanisms of Drug Interactions. In F. F. D'Arcy, J. C. McElnay, & P. G. Welling (Eds.), Handbook of Experimental Pharmacology (Vol. 122, pp. 173-212). 1982 Somogyi, A. A., & Eichelbaum, M. (1982). Pharmacokinetics, bioavailability and ECG response of verapamil in man. In M. Kaltenbach, & S. E. Epstein (Eds.), Hypertrophic Cardiomyopathy (pp. 291). 1980 Somogyi, A. A. (1980). Disposition of non-depolarizing muscle relaxants. In C. Conseiller, J. M. Desmonts, P. Glaser, J. Montagne, G. G. Nahas, J. C. Salamagne, . . . G. Vourc'h (Eds.), Curares and Curarisation (pp. 197-207). 1980 Somogyi, A. A., & Gugler, R. (1980). Methods in Clinical Pharmacology. In N. Rietbrock, B. G. Woodcock, & G. Neuhaus (Eds.), Methods in Clinical Pharmacology (pp. 242-249). -
Conference Papers
Year Citation 2022 Kisely, S., Connor, M., & Somogyi, A. (2022). DO PSILOCYBIN OR METHYLENEDIOXYME THAMPHETAMINE (MDMA) IMPROVE MENTAL, BEHAVIOURAL OR DEVELOPMENTAL DISORDERS EITHER AS STAND-ALONE TREATMENTS OR IN COMBINATION WITH PSYCHOTHERAPY?. In AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY Vol. 56 (pp. 179). SAGE PUBLICATIONS LTD. 2019 Wang, D., Wu, J., Rowsell, L., Wong, K., Yee, B., Somogyi, A., & Grunstein, R. (2019). THE EFFECT OF MORPHINE ON SLEEP: IS THERE A GENETIC EFFECT? - AN RCT STUDY. In SLEEP MEDICINE Vol. 64 (pp. S409). ELSEVIER. 2018 Ilyas, F., Somogyi, A., & Gabb, G. (2018). THERAPEUTIC DRUG SAFETY, IMPORTANT TO 'CLOSE THE GAP' FOR ABORIGINAL AND TORRES STRAIT ISLANDERS: A CASE OF PHENYTOIN HYPERSENSITIVITY SYNDROME. In INTERNAL MEDICINE JOURNAL Vol. 48 (pp. 12). WILEY. 2016 Hu, R. (2016). CYP3A5*3 and ABCB1 haplotype 61A-1199G-1236T-2677T/A-3435T are associated with dose-adjusted trough blood tacrolimus concentration in kidney transplant recipients. In ASCEPT-MPGPCR 2016. Melbourne, Australia. 2016 Rowsell, L., Yee, B., Wong, K., Somogyi, A., Eckert, D., Grunstein, R., & Wang, D. (2016). THE PHARMACOGENOMICS OF MORPHINE EFFECT ON OBSTRUCTIVE SLEEP APNEA: A RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED CROSSOVER TRIAL. In JOURNAL OF SLEEP RESEARCH Vol. 25 (pp. 6-7). WILEY-BLACKWELL. 2012 Wang, D., Somogyi, A., Yee, B., Wong, K., Kaur, J., Wrigley, P., & Grunstein, R. (2012). The effects of morphine on chemoreflexes and breathing in obstructive sleep apnoea. In JOURNAL OF SLEEP RESEARCH Vol. 21 (pp. 63-64). Paris, FRANCE: WILEY-BLACKWELL. 2011 Wang, D., Somogyi, A., Yee, B., Wong, K., Singh, J., Wrigley, P., & Grunstein, R. (2011). Can minocycline reverse morphine-induced respiratory depression in obstructive sleep apnea patients?. In JOURNAL OF SLEEP RESEARCH Vol. 20 (pp. 62-63). Sydney, AUSTRALIA: WILEY-BLACKWELL. 2011 Wang, J., Hughes, T. P., Kok, C. H., Saunders, V. A., Frede, A., GrootObbink, K., . . . White, D. L. (2011). Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy. In BLOOD Vol. 118 (pp. 1493-1494). San Diego, CA: AMER SOC HEMATOLOGY. 2011 Sallustio, B. C., Noll, B., Coller, J., Somogyi, A., van Gelder, T., Hesselink, D., & Morris, R. G. (2011). LC-MS/MS quantification of tacrolimus concentrations in small samples of kidney and liver tissue. In THERAPEUTIC DRUG MONITORING Vol. 33 (pp. 540). Stuttgart, GERMANY: LIPPINCOTT WILLIAMS & WILKINS. 2009 Somogyi, A. A., Gelston, E., Coller, J. K., White, J. M., & Schmidt, H. (2009). Methadone Inhibits CYP2D6 and UGT2B7 <i>In Vivo</i>: a Study using Codeine as the Substrate. In DRUG METABOLISM REVIEWS Vol. 41 (pp. 45-46). Lisbon, PORTUGAL: TAYLOR & FRANCIS INC.
WoS12009 Licari, J., Somogyi, A. A., Pierides, J., & Sallustio, B. C. (2009). Comparison of sprague dawley and dark agouti rats as animal models of perhexiline-induced hepatotoxicity. In DRUG METABOLISM REVIEWS Vol. 41 (pp. 128). Baltimore, MD: TAYLOR & FRANCIS INC. 2007 Sallustio, B. C., Davies, B. J., Herbert, M. K., Coller, J. K., Somogyi, A. A., & Milne, R. W. (2007). Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 extensive and poor metabolisers. In THERAPEUTIC DRUG MONITORING Vol. 29 (pp. 478). Nice, FRANCE: LIPPINCOTT WILLIAMS & WILKINS. 2007 Somogyi, A., Culler, J., Hallinan, R., & Foster, D. (2007). Pharmacokinetics and pharmacogenomics of high dose methadone in maintenance subjects. In THERAPEUTIC DRUG MONITORING Vol. 29 (pp. 485-486). Nice, FRANCE: LIPPINCOTT WILLIAMS & WILKINS. 2006 James, H., Gillis, D., Hissaria, P., Lester, S., Somogyi, A., Cleland, L., & Proudman, S. (2006). Polymorphisms in the folate pathway predict response to methotrexate in early RA.. In ARTHRITIS AND RHEUMATISM Vol. 54 (pp. S129). Washington, DC: WILEY-LISS. 2006 Somogyi, A., Nguyen, M., Lopatko, O., Foster, D., & White, J. (2006). Comparison of pharmacokinetics and pharmacodynamics of R-, S- and racemic-methadone in healthy subjects. In ACTA PHARMACOLOGICA SINICA Vol. 27 (pp. 418). BLACKWELL PUBLISHING. 2005 Morrish, G. A., Somogyi, A. A., & Foster, D. J. R. (2005). Population pharmacokinetic analysis of morphine in opioid dependent and control subjects. In DRUG METABOLISM REVIEWS Vol. 37 (pp. 60). Nice, FRANCE: TAYLOR & FRANCIS INC. 2004 Morton, E. B., Somogyi, A. A., Bochner, F., & White, J. M. (2004). The clinical pharmacology of methadone induction. In CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY Vol. 31 (pp. A226-A227). Brisbane, AUSTRALIA: BLACKWELL PUBLISHING ASIA. 2003 Drescher, S., Glaeser, H., Hofmann, U., Somogyi, A. A., Eichelbaum, M., & Fromm, M. F. (2003). Rate of intraluminal drug delivery determines bioavailability of verapamil. In DRUG METABOLISM REVIEWS Vol. 35 (pp. 68). DIJON, FRANCE: MARCEL DEKKER INC.
WoS22001 Somogyi, A., Athanasos, P., White, J., & Bochner, F. (2001). Respiratory depression and methadone induction. In TOXICOLOGY Vol. 164 (pp. 42). ELSEVIER SCI IRELAND LTD. 1996 Somogyi, A. (1996). Renal transport of drugs: Specificity and molecular mechanisms. In Clinical and Experimental Pharmacology and Physiology Vol. 23 (pp. 986-989). ADELAIDE, AUSTRALIA: BLACKWELL SCIENCE.
DOI Scopus40 WoS28 Europe PMC181990 Bochner, F., Chen, Z. R., Young, G., Somogyi, A., & Reynolds, G. (1990). Codeine disposition and metabolism: Comparison in young and elderly subjects. In European Journal of Pharmacology Vol. 183 (pp. 630-631). ELSEVIER SCIENCE BV.
DOI Scopus3 WoS21983 GUGLER, R., MULLERLIEBENAU, B., & SOMOGYI, A. (1983). ALTERED DISPOSITION AND AVAILABILITY OF CIMETIDINE IN PATIENTS WITH LIVER-CIRRHOSIS. In CLINICAL PHARMACOLOGY & THERAPEUTICS Vol. 33 (pp. 217). MOSBY-YEAR BOOK INC. 1983 SOMOGYI, A., MCLEAN, A., & HEINZOW, B. (1983). INFLUENCE OF CIMETIDINE ON PROCAINAMIDE PHARMACOKINETICS IN MAN. In CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY Vol. 10 (pp. 720). BLACKWELL SCIENCE. 1983 CHING, M. S., MORGAN, D. J., RAYMOND, K., BURY, R. W., MASHFORD, M. L., GURR, F. W., & SOMOGYI, A. A. (1983). ELIMINATION OF AMPHOTERICIN-B IN PATIENTS WITH IMPAIRED RENAL-FUNCTION. In CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY Vol. 10 (pp. 646). BLACKWELL SCIENCE. 1980 SOMOGYI, A. A., ROHNER, H. G., & GUGLER, R. (1980). CIMETIDINE PHARMACOKINETICS IN ULCER PATIENTS. In CLINICAL PHARMACOLOGY & THERAPEUTICS Vol. 27 (pp. 287). MOSBY-YEAR BOOK INC.
WoS11980 GUGLER, R., DJOJOWINARTO, H., KLIEMS, G., & SOMOGYI, A. A. (1980). CIMETIDINE DISPOSITION IN PATIENTS WITH PARTIAL GASTRECTOMY. In CLINICAL PHARMACOLOGY & THERAPEUTICS Vol. 27 (pp. 256-257). MOSBY-YEAR BOOK INC. 1979 SOMOGYI, A. A., TRIGGS, E. J., & SHANKS, C. A. (1979). PHARMACOKINETICS AND DURATION OF ACTION OF PANCURONIUM IN PATIENTS WITH TOTAL BILIARY OBSTRUCTION. In NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY Vol. 307 (pp. R74). SPRINGER VERLAG. 1979 GUGLER, R., DJOWINARTO, H., KLIEMS, G., & SOMOGYI, A. A. (1979). KINETICS OF CIMETIDINE IN PATIENTS AFTER BILLROTH GASTRECTOMIES I AND II. In ZEITSCHRIFT FUR GASTROENTEROLOGIE Vol. 17 (pp. 640-641). DEMETER VERLAG.
WoS1 -
Conference Items
Year Citation 2024 Martin, D., Harvey, A., Baune, B., Berk, M., Carter, G., Dong, V., . . . Loo, C. (2024). Cognitive Outcomes Following a Course of Racemic Ketamine: Results From the Randomised, Active-Controlled Ketamine for Adult Depression Study (KADS). Poster session presented at the meeting of Abstracts of the 79th Annual Meeting of the Society of Biological Psychiatry (SOBP 2024) as published in Biological Psychiatry. Austin, Texas, USA: Elsevier.
DOI2020 Ferreira, D., Barratt, D., Somogyi, A., & Currow, D. (2020). Genetics of response to sustained-release morphine for chronic breathlessness - an exploratory study. Poster session presented at the meeting of EUROPEAN RESPIRATORY JOURNAL. EUROPEAN RESPIRATORY SOC JOURNALS LTD.
DOI2015 Dom, Z. M., Coller, J., Carroll, R., Somogyi, A., & Sallustio, B. (2015). Intra-Lymphocyte Concentrations of Mycophenolic Acid Correlate With the Incidence of Early Graft Rejection in Renal Transplant Recipients. Poster session presented at the meeting of AMERICAN JOURNAL OF TRANSPLANTATION. Philadelphia, PA: WILEY-BLACKWELL. 2015 Somogyi, A. A. (2015). Translation of Opioid Pharmacogenomics into Pain Treatment: Commercial Reality versus Regulatory Oversight. Poster session presented at the meeting of PUBLIC HEALTH GENOMICS. KARGER. 2015 Dom, Z. I. M., Westley, I. S., Coller, J. K., Somogyi, A. A., & Sallustio, B. C. (2015). Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of mycophenolic acid in renal transplant recipients. Poster session presented at the meeting of Abstracts of the 2015 Golden Helix Symposium - Next Generation Pharmacogenomics, as published in Public Health Genomics. Karger.
DOI WoS12014 Li, Y., Coller, J., Hutchinson, M., Klein, K., Zanger, U., Currow, D., . . . Somogyi, A. (2014). Cyp2B6*6 Allele Alters Ketamine'S Pharmacokinetics In Chronic Pain Patients And Metabolism In Vitro. Poster session presented at the meeting of Drug Metabolism Reviews. Toronto, CANADA: Informa Healthcare.
DOI Europe PMC22014 Loo, C. K., Galvez, V., O'Keefe, E., Glue, P., Somogyi, A., & Shannon-Weickert, C. (2014). Ketamine as an Antidepressant: Investigating New Methods of Administration. Poster session presented at the meeting of BIOLOGICAL PSYCHIATRY. New York, NY: ELSEVIER SCIENCE INC. 2013 Sallustio, B., Noll, B., Coller, J., & Somogyi, A. (2013). Association Between Intra-Renal P-gp Expression and Cyclosporine Concentrations in Renal Transplantation. Poster session presented at the meeting of THERAPEUTIC DRUG MONITORING. Salt Lake City, UT: LIPPINCOTT WILLIAMS & WILKINS. 2013 Dom, M. Z., Coller, J. K., Somogyi, A. A., & Sallustio, B. C. (2013). Impact of Recipient and Donor Multidrug Resistance Protein 2 Genetic Variability on Mycophenolic Acid Pharmacokinetics Following Kidney Transplantation. Poster session presented at the meeting of THERAPEUTIC DRUG MONITORING. Salt Lake City, UT: LIPPINCOTT WILLIAMS & WILKINS. 2012 Coller, J., Hutchinson, M., Tuke, J., White, J., & Somogyi, A. (2012). 65. Association between immune genetic markers and opioid dependence. Poster session presented at the meeting of Brain, Behavior, and Immunity.
DOI2011 Somogyi, A. A., Coller, J. K., Foster, D. B. F., & Li, Y. (2011). ROLE OF CYP2B6 POLYMORPHISM IN THE METABOLISM AND PHARMACOKINETICS OF METHADONE ENANTIOMERS. Poster session presented at the meeting of BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. WILEY-BLACKWELL.
WoS12000 Olver, I., Vadas, M., Lopez, A., Keefe, D., Taylor, A., Brown, M., & To, L. (2000). A phase 1 study of the GM-CSF antagonist E21R. Poster session presented at the meeting of Proceedings of ASCO - Volume 19 2000. USA: American Society of Clinical Oncology.
DOI1986 MARLIN, G. E., BRAUDE, P. D., WHELAN, A. J., & SOMOGYI, A. A. (1986). BRONCHIAL MUCOSAL CONCENTRATIONS OF A NEW ORAL ANTIPSEUDOMONAL ANTIBIOTIC, ENOXACIN. Poster session presented at the meeting of AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE. ADIS PRESS AUSTRALASIA P/L.
| Date | Project Title / No. | Investigators | Funding Body | Amount |
|---|---|---|---|---|
| 2016 - 2018 |
Ketamine therapy among patients with treatment-resistant depression: a randomised, double-blind placebo-controlled trial. |
Loo C, Mitchell P, Glue P, Fitzgerald PB, Glozier N, Lapidus K, Hadzi-Pavlovic D, Somogyi A, Hackett M, Galvez V | NHMRC | $2,069,381 |
| 2015 - 2017 |
Personalised Medicines for Aboriginal Peoples |
Somogyi AA, Jamieson L, Dettwiller P | NHMRC | $1,066,571 |
| 2014 - 2017 |
Improving the treatment of breathlessness- a phase III randomised, controlled trial of sustained released morphine for the symptomatic treatment of of chronic refractory breathlessness. |
Currow D, Abernethy A, McDonald C, Miners J, Johnson M, Quinn S, Kirkpatrick C, Somogyi A, Denehy L, McCaffery N | NHMRC | $860,807 |
| 2014- 2015 |
Predictors of persistent postsurgical pain following total knee joint arthroplasty. |
MT Kluger, PJ McNair, AA Somogyi, GN Lewis | Australian and New Zealand College of Anaesthetists | $36000 |
| 2013 - 2015 |
Evaluating the effect of morphine on obstructive sleep apnoea. |
Wang D, Eckert D, Somogyi A, Grunstein R, Wong K | NHMRC | $515,779 |
| 2001 - 2004 | Pain and Analgesic Response in Opiate Dependence | W Ling, K Miotto, J White, A Somogyi, F Bochner | National Institutes of Health | $1, 591, 603 |
| 2009 - 2011 |
The role of OCT-1 Activity enhancers in improving the response of patients with low OCT-1 activity to imatinib. |
White D, Hughes T, Somogyi A, Melo J |
Leukemia and Lymphoma Society Translational Research Grant |
$600, 000 |
| 2011 - 2012 | Signalling pathway pharmacogenomics and opioid response: beyond the mu opioid receptor. | Somogyi AA (CIA) | NHMRC | $240, 000 |
| 1983 -present |
24 grants |
Multiple researchers |
NHRMC |
$13, 000, 000 |
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2021 Co-Supervisor Investigation of Genetic Polymorphisms That Could Interfere With Drug Metabolism of Omeprazole in Horses Doctor of Philosophy Doctorate Part Time Dr Gustavo Ferlini Agne -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2019 - 2023 Principal Supervisor Development and application of methods for pharmacokinetics (PK) analysis in PNG HIV/AIDS patients Doctor of Philosophy Doctorate Full Time Ms Natalia Bordin Andriguetti 2015 - 2019 Principal Supervisor Genetics of Tacrolimus Pharmacokinetics and Kidney Transplant Outcomes Doctor of Philosophy Doctorate Full Time Ms Rong Hu 2014 - 2015 Principal Supervisor Impact of CYP2C8 Single Nucleotide Polymorphisms on In-vitro Metabolism of Imatinib to N-desmethyl Imatinib Master of Philosophy (Medical Science) Master Full Time Mr Muhammad Suleman Khan 2011 - 2017 Co-Supervisor Mycophenolic Acid Pharmacokinetics and Clinical Outcomes in Renal Transplantation: Effect of ABCC2 Haplotype Analysis and Distribution into Lymphocytes and Kidney Doctor of Philosophy Doctorate Full Time Mr Zaipul Izwan Md Dom 2011 - 2017 Co-Supervisor Neuroimmunopharmacology of Opioids Doctor of Philosophy Doctorate Full Time Dr Jacob Henry Lloyd Thomas 2010 - 2014 Principal Supervisor Pharmacogenetics of Ketamine Metabolism and Immunopharmacology of Ketamine Doctor of Philosophy Doctorate Full Time Mr Yibai Li 2009 - 2011 Principal Supervisor CNS Immune Signalling and Drug Addiction: Role of Interleukin-1 Beta Doctor of Philosophy Doctorate Full Time Mr Liang Liu 2008 - 2011 Principal Supervisor The Neuroimmunopharmacology of Alcohol Doctor of Philosophy Doctorate Full Time Miss Yue Wu 2007 - 2011 Co-Supervisor Two methods of biomarker discovery: applications in neuropathic pain and pharmacotherapy Doctor of Philosophy Doctorate Full Time Mr Peter Grace 2007 - 2013 Co-Supervisor The Stereoselective Pharmacodynamics of the Enantiomers of Perherhexiline Doctor of Philosophy Doctorate Part Time Dr Johnny Licari 2006 - 2013 Principal Supervisor The Effect of Opioids on Emotional Reactivity Doctor of Philosophy Doctorate Full Time Mr Steven Savvas 2005 - 2010 Principal Supervisor Pharmacogenomics of ABCB1 in Maintenance Pharmacotherapies for Opioid Dependence Doctor of Philosophy Doctorate Full Time Dr Daniel Barratt 2003 - 2007 Co-Supervisor Evaluation and Treatment of Opioid-Induced Hyperalgesia Doctor of Philosophy Doctorate Full Time Mr Justin Hay 2003 - 2008 Co-Supervisor The Stereoselective Pharmacokinetics of the Enantiomers of Perhexiline in Poor and Extensive Metabolisers of the Cytochrome P450 2D6 Doctor of Philosophy Doctorate Full Time Mr Benjamin Davies 2002 - 2007 Co-Supervisor Clinical Pharmacology of Methadone Induction Doctor of Philosophy Doctorate Part Time Ms Erin Morton 2001 - 2005 Co-Supervisor ENHANCING THE USE OF OPIOIDS IN PAIN MANAGEMENT: ANTINOCICEPTIVE POTENTIATION WITH OPIOID AGONIST/ANTAGONIST COMBINATIONS Doctor of Philosophy Doctorate Full Time Dr Sophie La Vincente 2001 - 2013 Principal Supervisor Opioid Maintained Subjects and the Effects of High Dose Morphine and Adjuvant Analgesics Doctor of Philosophy Doctorate Full Time Mr Peter-Allan Athanasos 2000 - 2004 Co-Supervisor A comparison of methadone and slow-release oral morphine as maintenance pharmacotherapies for opioid dependence Doctor of Philosophy Doctorate Full Time Mr Timothy Mitchell 2000 - 2004 Principal Supervisor Opioids and Immune Function: The Role of Non-Classical Opioid Receptors and the Association with Pain Perception Doctor of Philosophy Doctorate Full Time Prof Mark Hutchinson 1998 - 2002 Co-Supervisor ACUTE PAIN MANAGEMENT IN METHADONE MAINTENANCE TREATMENT Doctor of Philosophy Doctorate Full Time Mr Mark Doverty 1997 - 2006 Co-Supervisor An Examination of the Pharmacodynamics and Pharmacokinetics of Levo-alpha-acetylmethadol (LAAM), compared to Methadone, in Opioid Maintenance Patients Doctor of Philosophy Doctorate Full Time Mr David Newcombe 1997 - 2010 Principal Supervisor The in vitro and in vivo Formation and Potency of 6 -Naltrexol, the Major Human Metabolite of Naltrexone Doctor of Philosophy Doctorate Full Time Ms Susan Porter
-
Board Memberships
Date Role Board name Institution name Country 1993 - 2000 Member Faculty of Science Board University of Adelaide Australia -
Committee Memberships
Date Role Committee Institution Country 2015 - ongoing Member Pharmacogenomics Executive Committee International Association of Therapeutic Drug Monitoring and Clinical Toxicology Australia 2015 - ongoing Chair Therapeutics Goods Committee Therapeutics Goods Administration, Department of Health, Canberra Australia 2014 - ongoing Member Pharmacogenetics Executive Committee International Union of Basic and Clinical Pharamacology - 2012 - ongoing Member Excellence in Research for Australia Research Evaluation Committee Australian Research Council Australia 2010 - ongoing Member Excellence in Research for Australia Research Evalutation Committee Australian Research Council Australia 2010 - 2014 Member Research Executive Committee University of Adelaide Australia 2004 - ongoing Member Research Committee, Faculty of Pain Medicine Australian and New Zealand College of Anaesthetists Australia 2002 - 2016 Member Advisory Committee on Nonprescription Medicine (ACNM) Department of Health (Canberra) Australia 2001 - 2005 Member Higher Degrees Committee University of Adelaide Australia 2000 - 2005 Member Grants and Personnel Subcomittee of Research Comittee University of Adelaide Australia 1999 - 2005 Member Research Committee University of Adelaide Australia 1998 - 1998 Member Organising Committee International Meeting of the International Society for the Study of Xenobiotics United States 1998 - 2000 Member Hospital Scientists Assessment Committee The Queen Elizabeth Hospital Australia 1995 - 1995 Chair Local Organising Comittee Annual Scientific Meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists - 1994 - 2011 Member Research Review Committee Royal Adelaide Hospital Australia 1994 - 1998 Member Division of Health Sciences Information Technology Committee University of Adelaide Australia 1994 - ongoing Member Research Ethics Committee Royal Adelaide Hospital - 1990 - 1996 Member Ethics of Human Research Committee The Queen Elizabeth Hospital Australia 1987 - 1987 Member Organising Committee International Symposium on Microsomes and Drug Oxidations Australia -
Memberships
Date Role Membership Country 2013 - ongoing Member Member NHMRC Grant Review Panel – 3B Australia 2010 - ongoing Member Member NHMRC Grant Review Panel – 3A Australia 2006 - 2009 Member Member of NHMRC Grant Review Panel –Pharmacology Australia 2005 - 2007 President The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Australia 2000 - 2002 Member NHMRC Discipline Panel Australia 1997 - 2000 Secretary The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Australia 1995 - 1996 Council The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Australia -
Editorial Boards
Date Role Editorial Board Name Institution Country 2010 - 2014 Editor European Journal of Clinical Pharmacology - - 2010 - ongoing Member Pharmacogenomics and Personalized Medicine - - 2007 - ongoing Member Journal of Opioid Management: a medical journal of proper and adequate use - - 2007 - 2015 Editor British Journal of Clinical Pharmacology - Australia 2002 - ongoing Member Pharmacogenetics and Genomics - - 1998 - ongoing Member Australian Medicines Handbook - Australia
Connect With Me
External Profiles
